array:24 [
  "pii" => "S2341287923002788"
  "issn" => "23412879"
  "doi" => "10.1016/j.anpede.2023.11.009"
  "estado" => "S300"
  "fechaPublicacion" => "2023-12-01"
  "aid" => "3542"
  "copyright" => "Asociación Española de Pediatría"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "An Pediatr (Barc). 2023;99:403-21"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S1695403323002370"
      "issn" => "16954033"
      "doi" => "10.1016/j.anpedi.2023.11.004"
      "estado" => "S300"
      "fechaPublicacion" => "2023-12-01"
      "aid" => "3542"
      "copyright" => "Asociación Española de Pediatría"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "An Pediatr (Barc). 2023;99:403-21"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a</span>"
        "titulo" => "Documento de consenso de la Sociedad Espa&#241;ola de Infectolog&#237;a Pedi&#225;trica y el Comit&#233; Asesor de Vacunas de la Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a para la vacunaci&#243;n en inmunodeprimidos"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "403"
            "paginaFinal" => "421"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Consensus document of the Spanish Society of Paediatric Infectious Diseases and the Advisory Committee on Vaccines of the Spanish Association of Pediatrics for vaccination of immunosuppressed individuals"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Irene Rivero Calle, Teresa del Rosal Rabes, Elisa Garrote Llanos, Esmeralda N&#250;&#241;ez Cuadros, Mar&#237;a Luisa Navarro G&#243;mez, Jos&#233; Tom&#225;s Ramos Amador, Cristina Calvo, Francisco &#193;lvarez Garc&#237;a"
            "autores" => array:9 [
              0 => array:2 [
                "nombre" => "Irene"
                "apellidos" => "Rivero Calle"
              ]
              1 => array:2 [
                "nombre" => "Teresa"
                "apellidos" => "del Rosal Rabes"
              ]
              2 => array:2 [
                "nombre" => "Elisa"
                "apellidos" => "Garrote Llanos"
              ]
              3 => array:2 [
                "nombre" => "Esmeralda"
                "apellidos" => "N&#250;&#241;ez Cuadros"
              ]
              4 => array:2 [
                "nombre" => "Mar&#237;a Luisa"
                "apellidos" => "Navarro G&#243;mez"
              ]
              5 => array:2 [
                "nombre" => "Jos&#233; Tom&#225;s"
                "apellidos" => "Ramos Amador"
              ]
              6 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Calvo"
              ]
              7 => array:2 [
                "nombre" => "Francisco"
                "apellidos" => "&#193;lvarez Garc&#237;a"
              ]
              8 => array:1 [
                "colaborador" => "Grupo de colaboradores del Documento de Consenso SEIP-CAV de la AEP"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2341287923002788"
          "doi" => "10.1016/j.anpede.2023.11.009"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923002788?idApp=UINPBA00005H"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403323002370?idApp=UINPBA00005H"
      "url" => "/16954033/0000009900000006/v1_202312041657/S1695403323002370/v1_202312041657/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2341287923002557"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2023.09.014"
    "estado" => "S300"
    "fechaPublicacion" => "2023-12-01"
    "aid" => "3524"
    "copyright" => "Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "An Pediatr &#40;Barc&#41;. 2023;99:422-30"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>"
      "titulo" => "Implementation of programmes for the transition of adolescents to adult care"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "422"
          "paginaFinal" => "430"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Implementaci&#243;n de programas de transici&#243;n de la adolescencia a la edad adulta"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1467
              "Ancho" => 3460
              "Tamanyo" => 329335
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0225"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Levels of complexity in the care transition model&#46; Adapted from Szalda D et al&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> with the permission of Elsevier&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Antonio Moreno-Gald&#243;, Maria Creu Regn&#233;-Alegret, Mar&#237;a Angeles Aceituno-L&#243;pez, Mar&#237;a Camprod&#243;n-G&#243;mez, Sergi Mart&#237;-Beltran, Roser Lara-Fern&#225;ndez, Mireia del-Toro-Riera"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Moreno-Gald&#243;"
            ]
            1 => array:2 [
              "nombre" => "Maria Creu"
              "apellidos" => "Regn&#233;-Alegret"
            ]
            2 => array:2 [
              "nombre" => "Mar&#237;a Angeles"
              "apellidos" => "Aceituno-L&#243;pez"
            ]
            3 => array:2 [
              "nombre" => "Mar&#237;a"
              "apellidos" => "Camprod&#243;n-G&#243;mez"
            ]
            4 => array:2 [
              "nombre" => "Sergi"
              "apellidos" => "Mart&#237;-Beltran"
            ]
            5 => array:2 [
              "nombre" => "Roser"
              "apellidos" => "Lara-Fern&#225;ndez"
            ]
            6 => array:2 [
              "nombre" => "Mireia"
              "apellidos" => "del-Toro-Riera"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403323002126"
        "doi" => "10.1016/j.anpedi.2023.09.016"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403323002126?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923002557?idApp=UINPBA00005H"
    "url" => "/23412879/0000009900000006/v1_202312211250/S2341287923002557/v1_202312211250/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2341287923002600"
    "issn" => "23412879"
    "doi" => "10.1016/j.anpede.2023.11.006"
    "estado" => "S300"
    "fechaPublicacion" => "2023-12-01"
    "aid" => "3525"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "An Pediatr &#40;Barc&#41;. 2023;99:393-402"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Acceptance and socioeconomic inequalities in meningococcal B vaccination in the community of Madrid prior to its inclusion in the immunization schedule"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "393"
          "paginaFinal" => "402"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Aceptaci&#243;n y desigualdades socioecon&#243;micas en la vacunaci&#243;n frente a meningococo B en la Comunidad de Madrid en el periodo anterior a su inclusi&#243;n en el calendario"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0040"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 825
              "Ancho" => 1333
              "Tamanyo" => 168756
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marta Ijalba Mart&#237;nez, Mar&#237;a Dolores Lasheras Carbajo, Sara Santos Sanz, Diana G&#243;mez Barroso"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Ijalba Mart&#237;nez"
            ]
            1 => array:2 [
              "nombre" => "Mar&#237;a Dolores"
              "apellidos" => "Lasheras Carbajo"
            ]
            2 => array:2 [
              "nombre" => "Sara"
              "apellidos" => "Santos Sanz"
            ]
            3 => array:2 [
              "nombre" => "Diana"
              "apellidos" => "G&#243;mez Barroso"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0040"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1695403323002138"
        "doi" => "10.1016/j.anpedi.2023.09.017"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403323002138?idApp=UINPBA00005H"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923002600?idApp=UINPBA00005H"
    "url" => "/23412879/0000009900000006/v1_202312211250/S2341287923002600/v1_202312211250/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Spanish Association of Paediatrics</span>"
    "titulo" => "Consensus document of the Spanish Society of Paediatric Infectious Diseases and the Advisory Committee on Vaccines of the Spanish Association of Pediatrics for vaccination of immunosuppressed individuals"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "403"
        "paginaFinal" => "421"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Irene Rivero Calle, Teresa del Rosal Rabes, Elisa Garrote Llanos, Esmeralda N&#250;&#241;ez Cuadros, Mar&#237;a Luisa Navarro G&#243;mez, Jos&#233; Tom&#225;s Ramos Amador, Cristina Calvo, Francisco &#193;lvarez Garc&#237;a"
        "autores" => array:9 [
          0 => array:4 [
            "nombre" => "Irene"
            "apellidos" => "Rivero Calle"
            "email" => array:1 [
              0 => "irene.rivero.calle@sergas.es"
            ]
            "referencia" => array:4 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
              3 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Teresa"
            "apellidos" => "del Rosal Rabes"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Elisa"
            "apellidos" => "Garrote Llanos"
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Esmeralda"
            "apellidos" => "N&#250;&#241;ez Cuadros"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Mar&#237;a Luisa"
            "apellidos" => "Navarro G&#243;mez"
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Jos&#233; Tom&#225;s"
            "apellidos" => "Ramos Amador"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Calvo"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Francisco"
            "apellidos" => "&#193;lvarez Garc&#237;a"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          8 => array:2 [
            "colaborador" => "Grupo de colaboradores del Documento de Consenso SEIP-CAV de la AEP"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">1</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:10 [
          0 => array:3 [
            "entidad" => "Servicio de Pediatr&#237;a&#44; Hospital Cl&#237;nico Universitario de Santiago de Compostela&#44; Grupo Gen&#233;tica&#44; Vacunas&#44; Infecciones y Pediatr&#237;a &#40;GENVIP&#41;&#44; Instituto de Investigaci&#243;n Hospital Cl&#237;nico Universitario de Santiago de Compostela &#40;IdiCHUS&#41;&#44; CIBERes Ciber de Respiratorio&#44; Santiago de Compostela&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Pediatr&#237;a&#44; Enfermedades Infecciosas y Tropicales&#44; Hospital Universitario La Paz&#44; Instituto de Investigaci&#243;n Hospital Universitario La Paz &#40;IdiPaz&#41;&#44; CIBERER U767&#44; Instituto de Salud Carlos III&#44; Madrid&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Secci&#243;n de Infectolog&#237;a&#44; Servicio de Pediatr&#237;a&#44; Hospital Universitario&#44; OSI Bilbao-Basurto&#44; Bilbao&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Secci&#243;n de Reumatolog&#237;a Pedi&#225;trica&#44; UGC Pediatr&#237;a&#44; Hospital Regional Universitario de M&#225;laga&#44; Grupo multidisciplinar pedi&#225;trico IBIMA&#44; M&#225;laga&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Pediatr&#237;a&#44; Hospital General Universitario Gregorio Mara&#241;&#243;n&#44; Instituto de Investigaci&#243;n Sanitaria Hospital Gregorio Mara&#241;&#243;n &#40;IISGM&#41;&#44; CIBERINFEC Ciber de Enfermedades Infecciosas&#44; Universidad Complutense&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio Pediatr&#237;a y &#193;reas Espec&#237;ficas&#44; Hospital Cl&#237;nico San Carlos&#44; Madrid&#44; Instituto de Investigaci&#243;n Sanitaria Hospital Cl&#237;nico San Carlos &#40;IdISSC&#41;&#44; Departamento de Salud P&#250;blica y Maternoinfantil&#44; Universidad Complutense&#44; CIBERINFEC Ciber de Enfermedades Infecciosas&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Pediatr&#237;a&#44; Enfermedades Infecciosas y Tropicales&#44; Hospital Universitario La Paz&#44; CIBERINFEC Ciber de Enfermedades Infecciosas&#44; Universidad Aut&#243;noma de Madrid&#44; Madrid&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Centro de Salud de Llanera&#44; Asturias&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Sociedad Espa&#241;ola de Infectolog&#237;a Pedi&#225;trica"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Comit&#233; Asesor de Vacunas de la AEP"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Documento de consenso de la Sociedad Espa&#241;ola de Infectolog&#237;a Pedi&#225;trica y el Comit&#233; Asesor de Vacunas de la Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a para la vacunaci&#243;n en inmunodeprimidos"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">In recent decades&#44; the number of people living with immunosuppression has been increasing due to their increased survival and the use of new immunosuppressive treatments for various chronic diseases&#46; This is a heterogeneous group of patients in whom immunosuppression may result from an inborn error of immunity or secondary to a disease or immunosuppressive therapy&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Depending on the cause of immunosuppression &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; the course of underlying disease and the treatments use&#44; the level of immune impairment can be mild&#44; moderate or severe&#44; and it can also remain stable&#44; vary or reverse over time&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#8211;3</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Immunosuppressed individuals are at increased risk of contracting vaccine-preventable diseases that can cause exacerbations of underlying disease and have a more severe course compared to immunocompetent individuals&#46; Therefore&#44; it is of utmost importance to optimise vaccination in this population&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In the context of immunosuppression&#44; the immune response to vaccines is suboptimal&#44; so vaccination should be performed at the earliest opportunity to achieve the best possible response&#44; preferably at the time of diagnosis&#44; but ensuring that necessary treatment is not deferred&#46; However&#44; misinformation and fears concerning the safety of vaccines or the course of underlying disease frequently result in undervaccination or delayed vaccination in immunosuppressed children&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">This document&#44; developed through the critical review of relevant scientific information obtained through a non-systematic review of published research and expert consensus documents&#44; provides guidelines to develop a personalised vaccination schedule for each patient&#46; It is divided in 6 sections&#58; &#40;a&#41; general recommendations&#44; &#40;b&#41; vaccination of haematopoietic stem cell transplant &#40;HSCT&#41; and solid organ transplant &#40;SOT&#41; recipients&#44; &#40;c&#41; vaccination of children with innate errors of immunity&#44; &#40;d&#41; vaccination of oncological patients&#44; &#40;e&#41; vaccination of patients with chronic or systemic diseases and &#40;f&#41; vaccination of immunosuppressed children who plan to travel&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">General recommendations for vaccination of immunosuppressed children and adolescents</span><p id="par0025" class="elsevierStylePara elsevierViewall">With the exceptions allowed for special situations&#44; immunosuppressed children and adolescents should receive all the vaccines in the routine immunization schedule in addition to those recommended to the specific group to which they belong&#46; The annual vaccine against the seasonal flu&#44; the pneumococcal vaccine and the SARS-CoV-2 vaccine are all recommended for immunosuppressed children in general&#44; to be given according to the current schedule for risk groups&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Inactivated vaccines do not pose a threat to the health of immunosuppressed patients&#44; although the immunogenicity will not be optimal and they may require additional primary series and&#47;or booster doses&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Live attenuated vaccines &#40;measles&#44; mumps and rubella &#91;MMR&#93;&#44; varicella&#44; rotavirus&#44; attenuated influenza&#44; oral typhoid fever&#44; yellow fever&#44; bacillus Calmette&#8211;Gu&#233;rin &#91;BCG&#93; and oral polio&#41; are contraindicated in severely immunosuppressed patients &#40;see <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41; due to the risk of replication and development of disease by vaccine strains&#46; Recent data have shown that these vaccines can be safe and immunogenic if the markers of humoral and cellular immunity are within specific ranges&#44; but further studies are required to confirm the recommendation of these vaccines under these circumstances&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">In the case of elective immunosuppression&#44; administration of all indicated vaccines with an accelerated schedule is recommended before initiation of immunosuppression&#44; administering live attenuated vaccines at least 4 weeks before and inactivated vaccines at least two weeks before&#46; After completion of treatment&#44; the recommended interval prior to vaccination ranges from 3 months to 2 years depending on the specific situation and type of vaccine&#46; <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> summarises the general recommendations for vaccination of immunosuppressed children and adolescents&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0045" class="elsevierStylePara elsevierViewall">Individuals vaccinated at intervals other than those recommended or during treatment should be considered as potential nonresponders and the need for a booster dose assessed&#44; performing serologic tests serving as correlates of protection&#44; when available&#44; a month after the administration of the most recent dose to guide revaccination&#44; and considering the use of passive immunoprophylaxis and&#47;or chemoprophylaxis in the case of exposure of individuals at risk&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Caregivers and household members should be fully and correctly vaccinated&#44; with particular emphasis on the MMR&#44; varicella&#44; seasonal influenza and SARS-CoV-2 vaccines&#46; The oral vaccines against poliovirus and <span class="elsevierStyleItalic">Salmonella typhi</span> Ty21 are contraindicated&#46; The intranasal live attenuated influenza vaccine can be administered to the close contacts of immunosuppressed patients with the exception of those who have undergone HSCT in the past 2 months&#44; with graft versus host disease &#40;GvHD&#41; or with severe combined immunodeficiency &#40;SCID&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">As a precaution&#44; immunosuppressed individuals should avoid contact with the faecal material of an infant vaccinated against rotavirus for 4 weeks following vaccination and&#44; in the case of close contacts who develop a rash after vaccination against varicella&#44; avoid contact with the lesions&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Vaccination in paediatric haematopoietic stem cell and solid organ transplant recipients</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Haematopoietic stem cell transplant recipients &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>&#41;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#8211;12</span></a></span><p id="par0060" class="elsevierStylePara elsevierViewall">Paediatric HSCT recipients experience immunosuppression to a degree that depends on the underlying disease and type of transplant&#44; and is most severe and lasting in the case of allogeneic transplants&#46; The changes in immunity result in decreased vaccine immunogenicity&#44; so some time must be allowed to pass after transplantation to implement an adapted immunization schedule to achieve complete vaccination&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">Vaccination against pneumococcal disease should start from 3 months from HSC transplantation with conjugate vaccines&#44; administering 3 doses at least 1 month apart and a fourth dose 6 months after the third&#46; In addition&#44; the remaining conjugate vaccines should be administered starting from 6 months post transplantation&#44; including the tetanus toxoid and reduced diphtheria toxoid and acellular pertussis &#40;Tdap&#41;&#44; inactivated poliovirus &#40;IPV&#41;&#44; hepatitis B &#40;HB&#41;&#44; <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b &#40;Hib&#41;&#44; meningococcal B&#47;ACWY and influenza vaccines&#46; During the flu season&#44; the influenza vaccine can be administered from 4 months post-HSCT&#44; and if the patient has GvHD&#44; a booster can be given 4&#8211;8 weeks later&#46; Immunization against human papillomavirus with 9-valent vaccine &#40;HPV9&#44; 3 doses&#41; is recommended starting at age 9 years&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">The MMR and varicella vaccines can be administered from 24 months &#40;2 doses at least 1 month apart&#41; as long as the patient does not have GvHD&#44; is not receiving immunosuppressant drugs&#44; has not received immunoglobulin replacement therapy in the past few months and the CD4 count is greater than 200&#47;mm<span class="elsevierStyleSup">3</span>&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Solid organ transplant recipients<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#44;9&#44;11&#44;12</span></a></span><p id="par0075" class="elsevierStylePara elsevierViewall">It is essential to vaccinate the patient as fully as possible before solid organ transplantation&#44; even by implementing an accelerated schedule&#46; After transplantation&#44; the recipient will be immunosuppressed so the response to inactivated vaccines will not be optimal and live attenuated vaccines will be contraindicated&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Vaccination before solid organ transplantation should stop at least 4 weeks prior in the case of live vaccines and 2 weeks prior in the case of inactivated vaccines&#46; Vaccination can resume 6 months after transplantation&#46;</p><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Before transplantation</span><p id="par0085" class="elsevierStylePara elsevierViewall">The MMR and varicella vaccines can be administered earlier than scheduled starting from age 6 months&#46; Administration of the HB and hepatitis A &#40;HA&#41; vaccines is indicated&#44; and assessment of immunity after vaccination is recommended &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#44; notes 3 and 4&#41;&#46; Ensuring correct vaccination against pneumococcal disease is essential&#46; Vaccination against huma papillomavirus with 3 doses of HPV9 is indicated for any age&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">After transplantation &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>&#41;</span><p id="par0090" class="elsevierStylePara elsevierViewall">Live vaccines &#40;MMR&#44; varicella&#44; rotavirus&#44; yellow fever&#44; oral typhoid fever&#41; are contraindicated&#46; In the case of inactivated vaccines&#44; even if the patient is fully vaccinated&#44; it is recommended to administer booster doses of IPV IPV&#44; DTaP&#47;Tdap&#44; pneumococcal vaccine and SARS-CoV-2 vaccine&#46; Administration of the influenza vaccine is recommended from 1 month post transplantation&#46; The patient should be given the pneumococcal vaccine with the highest valency available&#46; Performance of hepatitis A and B immunity tests is recommended after post-SOT &#40;see <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41; and every 2 years thereafter&#44; administering a booster dose if the test result is negative&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Vaccination of children with inborn errors of immunity</span><p id="par0095" class="elsevierStylePara elsevierViewall">Inborn errors of immunity &#40;IEIs&#41; are a heterogeneous group of diseases associated with a growing number of gene variants<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13&#44;14</span></a> and with a variable risk of infection&#44; so vaccination must be individualised in affected patients&#46; For practical purposes&#44; IEIs are classified into 3 groups&#58; defects in adaptive immunity&#44; defects in innate immunity and IEIs associated with characteristic phenotypes or syndromic immunodeficiencies&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Inborn errors of immunity carry an increased risk of vaccine-preventable diseases and a reduced immune response&#44; both in duration and intensity&#46; Nevertheless&#44; there is evidence of the protective effect of vaccination&#44; associated with a decrease in mortality and the incidence of complications&#44;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> which is why these patients usually require booster doses&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Live attenuated vaccines &#40;viral or bacterial&#41; carry a risk of dissemination in patients with defects in cell-mediated immunity&#44;<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15&#44;16</span></a> and while suspicion of an IEI is not sufficient reason to delay vaccination&#44; live attenuated vaccines are contraindicated until the level of immune impairment is established&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Inactivated or subunit vaccines are safe and can be effective&#46; In patients with IEIs requiring immunoglobulin replacement therapy&#44; live attenuated viral vaccines should not be administered for the next 3&#8211;11 months due to the interference of the treatment with the vaccine response&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Considering the above&#44; children IEIs generally require an expanded vaccination schedule&#44;<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17&#44;18</span></a> especially for protection against encapsulated bacteria&#58; pneumococcus&#44; meningococcus &#40;B&#47;ACWY&#41; and Hib&#44; and from 6 months&#44; annual vaccination against influenza with inactivated quadrivalent vaccine and against SARS-CoV-2 in adherence with current recommendations&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> It is also essential to promote the vaccination of household members and the general population&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a> presents an approximate vaccination schedule for the most frequent IEIs&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Vaccination of immunosuppressed children who are not transplant recipients&#58; oncological patients</span><p id="par0125" class="elsevierStylePara elsevierViewall">Immunosuppression in oncological paediatric patients persists for months after completion of treatment&#44; affecting the immunogenicity of vaccines administered before&#44; during or soon after chemotherapy&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#44;20&#44;21</span></a> In addition&#44; some patients may have anatomic or functional asplenia &#40;radiation therapy to the abdomen&#44; GvHD&#41;&#46; The evidence regarding vaccination in the context of novel immunotherapies is still insufficient&#46;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#44;21</span></a></p><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">General principles for vaccination of children managed with chemotherapy</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Before chemotherapy</span><p id="par0130" class="elsevierStylePara elsevierViewall">If feasible&#44; getting vaccination up to date according to the routine immunization schedule is recommended&#44; administering inactivated vaccines at least 2 weeks before and attenuated vaccines at least 4 weeks before initiation of chemotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">During chemotherapy</span><p id="par0135" class="elsevierStylePara elsevierViewall">Vaccines in the routine immunization schedule should not be administered during intensive chemotherapy&#46; The response to inactivated vaccines is very small &#40;vaccination would be considered to have failed&#41; and attenuated vaccines are contraindicated&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">In children receiving maintenance treatment for lymphoblastic leukaemia&#44; annual vaccination against influenza is recommended from age 6 months&#46; The guidelines of the European Conference on Infections in Leukaemia also recommend a PCV booster dose&#44;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> although the immune response may be suboptimal and administration of another dose is necessary after treatment has been completed&#46;<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22&#44;23</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">After chemotherapy</span><p id="par0145" class="elsevierStylePara elsevierViewall">Repeating primary vaccination with vaccines the child has already received is not necessary&#46; In fully vaccinated children&#44; administration of a booster dose of previously received vaccines is recommended&#44; after which vaccines should be administered according to the routine immunization schedule based on the age of the patient&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#44;21</span></a> If the vaccination was not up to date at initiation of chemotherapy&#44; catch-up vaccination will be the first step&#46; The schedule for catch-up vaccination&#44; including the number of doses of each vaccine&#44; the minimum age for administration and the minimum intervals between doses&#44; can be consulted in the tables published by the Advisory Committee on Vaccines of the AEP &#40;CAV-AEP&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">Inactivated vaccines should be administered between 3 and &#40;preferably&#41; 6 months after completion of chemotherapy&#44; while the administration of attenuated vaccines should be deferred to 6&#8211;12 months after &#40;preferably 12&#41;&#46; In regimes that include anti-B cell antibodies&#44; an interval of 6&#8211;12 months is recommended before administration of any vaccine&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8&#44;21</span></a> Recent data show that children with lymphoblastic leukaemia could receive the pneumococcal conjugate vaccine right after completing treatment&#44; as the response is similar to that of those vaccinated 6 months after&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Early administration of this vaccine could be contemplated&#44; especially in children who missed vaccination during maintenance chemotherapy&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Specific recommendations for vaccination of oncological patients</span><p id="par0155" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8211;</span><p id="par0160" class="elsevierStylePara elsevierViewall">Pneumococcal&#58; PCV15&#8239;&#43;&#8239;PCV23 sequence&#44; or PCV20 exclusively&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0165" class="elsevierStylePara elsevierViewall">Influenza&#58; annual inactivated vaccines&#44; at least the 3 seasons following completion of chemotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0170" class="elsevierStylePara elsevierViewall">SARS-CoV-2&#58; schedule depending on age and type of vaccine&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0175" class="elsevierStylePara elsevierViewall">HPV9&#58; recommended from age 9 years&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0180" class="elsevierStylePara elsevierViewall">The use of live attenuated vaccines is not recommended in patients treated with tyrosine-kinase inhibitors or ruxolitinib&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a></p></li></ul></p></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Vaccination of children with chronic diseases</span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Vaccination of children with autoimmune or autoinflammatory diseases receiving immunosuppressive treatment<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#8211;29</span></a></span><p id="par0185" class="elsevierStylePara elsevierViewall">The earliest recommendations of the European Alliance of Associations for Rheumatology &#40;EULAR&#41; were developed in 2011&#44; and many were extrapolated from the adult literature due to the low quality of the studies conducted in children&#46; Since then&#44; the evidence on the safety and immunogenicity of vaccines has doubled&#46;</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">General recommendations</span><p id="par0190" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">-</span><p id="par0195" class="elsevierStylePara elsevierViewall">If possible&#44; vaccines should be administered 2&#8211;4 weeks before initiation of immunosuppressive therapy &#40;especially in the case of B-cell depleting therapies&#41;&#44; but necessary treatment should never be deferred&#46; However&#44; the interval may vary depending on the type of drug &#40;see Table 14&#46;3 of the CAV-AEP at <a href="https://vacunasaep.org/documentos/manual/cap-14#7">https&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-14&#35;7</a>&#41;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">-</span><p id="par0200" class="elsevierStylePara elsevierViewall">Vaccination during the inactive phase of disease&#47;remission is advisable&#44; and it should not be delayed out of fear of triggering an exacerbation&#44; as there is no evidence of such an association&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">-</span><p id="par0205" class="elsevierStylePara elsevierViewall">All immunosuppressed patients must adhere to the routine vaccination schedule and travel vaccination requirements&#44; with the exception of live attenuated vaccines&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">-</span><p id="par0210" class="elsevierStylePara elsevierViewall">Inactivated vaccines can be administered to patients receiving corticosteroids or disease-modifying antirheumatic drugs &#40;DMARDs&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">-</span><p id="par0215" class="elsevierStylePara elsevierViewall">Live attenuated viral vaccines are contraindicated in patients with treatments resulting in high-level immunosuppression &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; with the exception of MMR booster doses and the varicella vaccine&#44; whose administration can be contemplated on a case-by-case basis under specific circumstances&#46;</p></li></ul></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Specific recommendations &#40;based on the 2021 EULAR recommendations&#41;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a></span><p id="par0220" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">-</span><p id="par0225" class="elsevierStylePara elsevierViewall">Vaccination against tetanus according to current general recommendations&#59; passive immunization is recommended for patients who have received B cell-depleting therapy in the past 6 months in whom administration of tetanus toxoid is indicated&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">-</span><p id="par0230" class="elsevierStylePara elsevierViewall">Administration of HPV9 should be considered in previously unvaccinated patients with systemic lupus erythematosus or inflammatory bowel disease &#40;3 doses if the patient receives immunosuppressive therapy&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">-</span><p id="par0235" class="elsevierStylePara elsevierViewall">Administration of the MMR booster dose could be considered on a case-by-case basis&#44; after assessment by the specialist in charge&#44; in patients receiving methotrexate &#40;MTX&#41; at immunomodulating doses &#40;A-level recommendation&#41; or low-dose steroids&#44; anti-TNF&#945;&#44; anti-IL-1 or anti-IL-6 &#40;C-level recommendation&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">-</span><p id="par0240" class="elsevierStylePara elsevierViewall">Administration of the varicella vaccine could be considered on a case-by-case basis&#44; after assessment by the specialist in charge&#44; in na&#239;ve patients receiving methotrexate &#40;MTX&#41; at immunomodulating doses A-level recommendation&#41; or low-dose steroids&#44; anti-TNF&#945;&#44; anti-IL-1 or anti-IL-6 &#40;D-level recommendation&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">-</span><p id="par0245" class="elsevierStylePara elsevierViewall">Vaccination against yellow fever should be avoided in any patient receiving immunosuppressive therapy &#40;D-level recommendation&#41;</p></li><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">-</span><p id="par0250" class="elsevierStylePara elsevierViewall">Vaccination against hepatitis A is recommended in patients treated with hepatotoxic immunosuppressive drugs &#40;MTX or tocilizumab&#41;&#46;</p></li></ul></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Kidney and liver diseases<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26&#44;31</span></a></span><p id="par0255" class="elsevierStylePara elsevierViewall">Vaccination against <span class="elsevierStyleBold">hepatitis B</span> is essential&#44; in addition to monitoring of the vaccine response&#46; Vaccination against <span class="elsevierStyleBold">hepatitis A</span> is also indicated&#44; with the standard schedule or alternatively with the combination vaccine &#40;A&#8239;&#43;&#8239;B&#41; if a booster dose of HB is required&#46; In the absence of immunosuppression&#44; vaccination against <span class="elsevierStyleBold">measles and varicella</span> is recommended as soon as possible after diagnosis&#46;</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Cardiovascular and respiratory diseases<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26</span></a></span><p id="par0260" class="elsevierStylePara elsevierViewall">This includes children with congenital heart diseases &#40;cyanotic diseases&#44; associated with heart failure or haemodynamic changes&#41;&#44; pulmonary hypertension&#44; bronchopulmonary dysplasia&#44; cystic fibrosis&#44; bronchiectasis and moderate to severe asthma&#46; Vaccination against <span class="elsevierStyleBold">varicella</span> according to the routine schedule is recommended&#44; with the qualification that in patients treated with salicylates it is considered preferable to discontinue treatment for 6 weeks after the administration of the vaccine &#40;if not possible&#44; the patient should still be vaccinated&#44; as there have been no reports of Reye syndrome associated with the vaccine-type virus&#41;&#46;</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Neurologic diseases<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26</span></a></span><p id="par0265" class="elsevierStylePara elsevierViewall">No vaccines are contraindicated for children with epilepsy&#46; In fact&#44; the use of the vaccine with acellular pertussis has been found to significantly decrease the incidence of febrile seizures associated with the diphtheria&#44; tetanus and whole-cell pertussis vaccines&#46; If the patient receives hepatotoxic drugs&#44; such as valproic acid&#44; vaccination against hepatitis A is recommended&#46;</p><p id="par0270" class="elsevierStylePara elsevierViewall">However&#44; in the presence of a progressive&#44; unstable or unspecified encephalopathy&#44; the administration of vaccines that could destabilize the patient &#40;like the pertussis vaccine&#41; should be deferred&#46; In the case of neurological autoimmune or inflammatory disease in which there are grounds to suspect an association with a given vaccine&#44; no other doses of the vaccine should be administered&#46;</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Genetic disorders &#40;Down syndrome&#41;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26</span></a></span><p id="par0275" class="elsevierStylePara elsevierViewall">Annual vaccination against influenza and vaccination against pneumococcal disease &#40;with PCV15&#8239;&#43;&#8239;PPSV23 or PCV20 exclusively&#41; and hepatitis A is recommended for children with Down syndrome&#46;</p><p id="par0280" class="elsevierStylePara elsevierViewall">For children with other genetic disorders&#44; specific vaccination requirements need only be assessed if there are chronic immune comorbidities&#46;</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Haemoglobin disorders<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26</span></a></span><p id="par0285" class="elsevierStylePara elsevierViewall">Children with haemoglobin disorders manifesting with functional hyposplenism must be vaccinated against pneumococcal disease &#40;with PCV15&#8239;&#43;&#8239;PPSV23 or PCV20&#41;&#44; Hib and meningococcal disease &#40;Men ACWY&#8239;&#43;&#8239;booster dose at 5 years and Men B with booster doses 1 year after completion of the primary series and every 5 years thereafter&#41;&#44; and also against hepatitis &#40;A and B&#41; due to the increased risk of liver disease&#46; It is important to consider the recommended intervals &#40;6&#8211;7 months&#41; between the transfusion of blood products and the administration of attenuated vaccines&#46; In Spain&#44; as long as there is no outbreak of measles&#44; mumps or rubella&#44; changes to the immunization schedule are not indicated if the patient is going to be treated with hydroxyurea in the first year of life&#46;</p><p id="par0290" class="elsevierStylePara elsevierViewall">Patients with beta thalassaemia <span class="elsevierStyleItalic">minor</span> or sickle cell trait should receive the same vaccines as the general population&#46;</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Cochlear implant<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;26</span></a></span><p id="par0295" class="elsevierStylePara elsevierViewall">Due to the risk of developing meningitis and otitis media&#44; vaccination against pneumococcal disease is particularly recommended &#40;with PCV15&#8239;&#43;&#8239;PPSV23 or PCV20&#41;&#44; in addition to Hib and annual vaccination against influenza&#46;</p><p id="par0300" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0030">Table 6</a> presents an approximate vaccination schedule for immunosuppressed children with chronic diseases&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia></span></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Vaccination of immunosuppressed children who plan to travel</span><p id="par0305" class="elsevierStylePara elsevierViewall">Before traveling&#44; immunosuppressed children should have their vaccines up to date&#44; and it is a good time to administer upcoming doses&#44; possibly earlier than established in the vaccination schedule&#44; if their immune status allows it&#46;<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32&#8211;39</span></a> Individualised guidance must be provided sufficiently in advance to ensure that administered vaccines are effective&#46; Thus&#44; it is recommended that the child make a visit between 4 and 6 weeks prior to the departure&#46; If it can be avoided&#44; immunosuppressed children aged less than 2 years should not travel&#46;</p><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Specific vaccination of travellers<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32&#8211;39</span></a></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Routine&#47;universal vaccines</span><p id="par0310" class="elsevierStylePara elsevierViewall">Those recommended in the routine vaccination schedule for children of the traveller&#8217;s age&#46; If the child&#8217;s vaccination is not up to date&#44; the missing doses will be administered before travel&#46; If the child is to travel to a country endemic for a disease against which the child has not been vaccinated&#44; such as measles or varicella&#44; the vaccine will be administered earlier than scheduled as long as it is possible&#46;</p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Specific vaccines for travellers &#40;see <a class="elsevierStyleCrossRef" href="#tbl0035">Table 7</a>&#41;</span><p id="par0315" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">&#8226;</span><p id="par0320" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleUnderline">Mandatory</span>&#58;</span> depending on the destination&#44; type of travel and age&#46; It includes those required by receiving countries for entry&#58; yellow fever&#44; meningococcal and poliovirus&#46; The authorities of countries with specific requirements will expect travellers to carry an International Certificate of Vaccination or Prophylaxis correctly recording the received vaccinations&#46;</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">&#8226;</span><p id="par0325" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleUnderline">Recommended depending on travel</span>&#58;</span> depending on the destination&#44; the risk assessment of the child and the type of travel&#46;</p><elsevierMultimedia ident="tbl0035"></elsevierMultimedia></li></ul></p></span></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Requirements based on the level of immunosuppression<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32&#8211;39</span></a></span><p id="par0330" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0040">Table 8</a> presents the specific recommendations for vaccination of immunosuppressed children who plan to travel&#46;</p><elsevierMultimedia ident="tbl0040"></elsevierMultimedia></span></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Funding</span><p id="par0335" class="elsevierStylePara elsevierViewall">This research project did not receive specific financial support from funding agencies in the public&#44; private or not-for-profit sectors&#46;</p></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Conflicts of interest &#40;last 5 years&#41;</span><p id="par0340" class="elsevierStylePara elsevierViewall">Irene Rivero Calle has collaborated in educational activities funded by GlaxoSmithKline&#44; MSD&#44; Pfizer and Sanofi Pasteur&#44; as a researcher in vaccine clinical trials for Abbot&#44; AstraZeneca&#44; Enanta&#44; Gilead&#44; GlaxoSmithKline&#44; HIPPRA&#44; Janssen&#44; Medimmune&#44; Merck&#44; Moderna&#44; MSD&#44; Novavax&#44; Pfizer&#44; Reviral&#44; Roche&#44; Sanofi and Seqirus&#59; and as a consultant in GlaxoSmithKline&#44; MSD&#44; Pfizer and Sanofi advisory boards&#46;</p><p id="par0345" class="elsevierStylePara elsevierViewall">Teresa del Rosal has received fees for participation in conferences and from research grants from MSD&#44; funding to attend educational activities from Pfizer and collaborated as researcher in clinical trials for GSK&#44; Janssen and MSD&#44; for which the institution she is affiliated with received fees&#46;</p><p id="par0350" class="elsevierStylePara elsevierViewall">Elisa Garrote has collaborated in educational activities funded by GlaxoSmithKline&#44; MSD&#44; Pfizer and Sanofi&#44; as a researcher in vaccine clinical trials for de GlaxoSmithKline&#44; and as a consultant in GlaxoSmithKline and MSD advisory boards&#46;</p><p id="par0355" class="elsevierStylePara elsevierViewall">Esmeralda N&#250;&#241;ez has collaborated in educational activities funded by Pfizer&#46;</p><p id="par0360" class="elsevierStylePara elsevierViewall">Mar&#237;a Luisa Navarro has collaborated in educational activities funded by Gilead&#44; GlaxoSmithKline&#44; Janssen&#44; MSD&#44; Pfizer and ViiV&#44; as a consultant in Abbott&#44; AstraZeneca&#44; Novartis&#44; Pfizer and ViiV advisory boards and in clinical trials funded by GlaxoSmithKline&#44; Pfizer&#44; Roche&#44; MSD&#44; Sanofi and Pfizer&#46;</p><p id="par0365" class="elsevierStylePara elsevierViewall">Jos&#233; Tomas has received fees for participation in conferences from Gilead&#44; GSK&#44; ViiF and Pfizer&#46; He has received grants or funding to attend training workshops from BioMerieux&#44; Gilead and Pfizer&#46; He has received fees as a consultant for Pfizer&#44; GSK and ViiF&#46; He has collaborated as the principal investigator of the centre in clinical trials of Pfizer&#44; GSK and Janssen&#44; for which his institution collected fees&#46;</p><p id="par0370" class="elsevierStylePara elsevierViewall">Cristina Calvo has received fees for participation in conferences from MSD and Pfizer&#46; She has received research grants&#47;funding from MSD and BioMerieux&#46; She has received fees as a consultant for Sanofi&#46; She has participated as a researcher in clinical trials conducted by Abbott&#44; MSD&#44; Pfizer&#44; Janssen&#44; GSK and Allergan&#44; for which her institution collected fees&#46;</p><p id="par0375" class="elsevierStylePara elsevierViewall">Francisco &#193;lvarez Garc&#237;a has received funding to attend domestic educational activities&#46; He has participated in educational activities funded by Alter&#44; AstraZeneca&#44; GSK&#44; Pfizer&#44; MSD and Sanofi and served as a consultant in GSK&#44; Pfizer&#44; MSD and Sanofi advisory boards&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres2054693"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1754412"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres2054692"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1754413"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "General recommendations for vaccination of immunosuppressed children and adolescents"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Vaccination in paediatric haematopoietic stem cell and solid organ transplant recipients"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Haematopoietic stem cell transplant recipients &#40;Table 3&#41;"
            ]
            1 => array:3 [
              "identificador" => "sec0025"
              "titulo" => "Solid organ transplant recipients"
              "secciones" => array:2 [
                0 => array:2 [
                  "identificador" => "sec0030"
                  "titulo" => "Before transplantation"
                ]
                1 => array:2 [
                  "identificador" => "sec0035"
                  "titulo" => "After transplantation &#40;Table 4&#41;"
                ]
              ]
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Vaccination of children with inborn errors of immunity"
        ]
        8 => array:3 [
          "identificador" => "sec0045"
          "titulo" => "Vaccination of immunosuppressed children who are not transplant recipients&#58; oncological patients"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0050"
              "titulo" => "General principles for vaccination of children managed with chemotherapy"
              "secciones" => array:3 [
                0 => array:2 [
                  "identificador" => "sec0055"
                  "titulo" => "Before chemotherapy"
                ]
                1 => array:2 [
                  "identificador" => "sec0060"
                  "titulo" => "During chemotherapy"
                ]
                2 => array:2 [
                  "identificador" => "sec0065"
                  "titulo" => "After chemotherapy"
                ]
              ]
            ]
            1 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Specific recommendations for vaccination of oncological patients"
            ]
          ]
        ]
        9 => array:3 [
          "identificador" => "sec0075"
          "titulo" => "Vaccination of children with chronic diseases"
          "secciones" => array:9 [
            0 => array:2 [
              "identificador" => "sec0080"
              "titulo" => "Vaccination of children with autoimmune or autoinflammatory diseases receiving immunosuppressive treatment"
            ]
            1 => array:2 [
              "identificador" => "sec0085"
              "titulo" => "General recommendations"
            ]
            2 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Specific recommendations &#40;based on the 2021 EULAR recommendations&#41;"
            ]
            3 => array:2 [
              "identificador" => "sec0095"
              "titulo" => "Kidney and liver diseases"
            ]
            4 => array:2 [
              "identificador" => "sec0100"
              "titulo" => "Cardiovascular and respiratory diseases"
            ]
            5 => array:2 [
              "identificador" => "sec0105"
              "titulo" => "Neurologic diseases"
            ]
            6 => array:2 [
              "identificador" => "sec0110"
              "titulo" => "Genetic disorders &#40;Down syndrome&#41;"
            ]
            7 => array:2 [
              "identificador" => "sec0115"
              "titulo" => "Haemoglobin disorders"
            ]
            8 => array:2 [
              "identificador" => "sec0120"
              "titulo" => "Cochlear implant"
            ]
          ]
        ]
        10 => array:3 [
          "identificador" => "sec0125"
          "titulo" => "Vaccination of immunosuppressed children who plan to travel"
          "secciones" => array:2 [
            0 => array:3 [
              "identificador" => "sec0130"
              "titulo" => "Specific vaccination of travellers"
              "secciones" => array:2 [
                0 => array:2 [
                  "identificador" => "sec0135"
                  "titulo" => "Routine&#47;universal vaccines"
                ]
                1 => array:2 [
                  "identificador" => "sec0140"
                  "titulo" => "Specific vaccines for travellers &#40;see Table 7&#41;"
                ]
              ]
            ]
            1 => array:2 [
              "identificador" => "sec0145"
              "titulo" => "Requirements based on the level of immunosuppression"
            ]
          ]
        ]
        11 => array:2 [
          "identificador" => "sec0150"
          "titulo" => "Funding"
        ]
        12 => array:2 [
          "identificador" => "sec0155"
          "titulo" => "Conflicts of interest &#40;last 5 years&#41;"
        ]
        13 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-10-02"
    "fechaAceptado" => "2023-11-13"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1754412"
          "palabras" => array:7 [
            0 => "Vaccination"
            1 => "Immunodeficiencies"
            2 => "Immunosuppressive therapy"
            3 => "Chronic illness"
            4 => "Transplants"
            5 => "Immunocompromised traveller"
            6 => "Human immunodeficiency virus"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1754413"
          "palabras" => array:7 [
            0 => "Vacunaci&#243;n"
            1 => "Inmunodeficiencias"
            2 => "Inmunosupresores"
            3 => "Enfermedades cr&#243;nicas"
            4 => "Trasplantados"
            5 => "Viajero inmunocomprometido"
            6 => "Virus de la inmunodeficiencia humana"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">The number of people with immunosuppression is increasing considerably due to their greater survival and the use of new immunosuppressive treatments for various chronic diseases&#46; This is a heterogeneous group of patients in whom vaccination as a preventive measure is one of the basic pillars of their wellbeing&#44; given their increased risk of contracting infections&#46; This consensus&#44; developed jointly by the Sociedad Espa&#241;ola de Infectolog&#237;a Pedi&#225;trica &#40;Spanish Society of Pediatric Infectious Diseases&#41; and the Advisory Committee on Vaccines of the Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a &#40;Spanish Association of Paediatrics&#41;&#44; provides guidelines for the development of a personalised vaccination schedule for patients in special situations&#44; including general recommendations and specific recommendations for vaccination of bone marrow and solid organ transplant recipients&#44; children with inborn errors of immunity&#44; oncologic patients&#44; patients with chronic or systemic diseases and immunosuppressed travellers&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">El n&#250;mero de personas con inmunodepresi&#243;n est&#225; aumentando considerablemente debido a su mayor supervivencia y al empleo de nuevas terapias inmunosupresoras en diversas patolog&#237;as cr&#243;nicas&#46; Se trata de un grupo heterog&#233;neo de pacientes en los que la vacunaci&#243;n como arma preventiva supone uno de los pilares b&#225;sicos de su bienestar&#44; por su elevado riesgo a padecer infecciones&#46; Este consenso&#44; elaborado conjuntamente entre la Sociedad Espa&#241;ola de Infectolog&#237;a Pedi&#225;trica &#40;SEIP&#41; y el Comit&#233; Asesor de Vacunas de la Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a &#40;CAV-AEP&#41;&#44; aporta unas directrices para programar un calendario adaptado a cada paciente en situaciones especiales que incluye recomendaciones generales&#44; vacunaci&#243;n en pacientes con trasplante de m&#233;dula y trasplante de &#243;rgano s&#243;lido&#44; vacunaci&#243;n en ni&#241;os con errores innatos de la inmunidad&#44; vacunaci&#243;n en el paciente oncol&#243;gico&#44; vacunaci&#243;n en pacientes con enfermedades cr&#243;nicas o sist&#233;micas y vacunaci&#243;n en ni&#241;os viajeros inmunodeprimidos&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "1"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0155">The members of the Advisory Committee on Vaccines of the Asociaci&#243;n Espa&#241;ola De Pediatr&#237;a are listed in Annex <a class="elsevierStyleCrossRef" href="#sec0160">A</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0380" class="elsevierStylePara elsevierViewall">Francisco Jos&#233; &#193;lvarez Garc&#237;a &#40;FJAG&#41;&#44; Antonio Iofr&#237;o de Arce &#40;AIA&#41;&#44; Javier &#193;lvarez Alde&#225;n &#40;JAA&#41;&#44; Mar&#237;a Garc&#233;s-S&#225;nchez &#40;MGS&#41;&#44; Elisa Garrote Llanos &#40;EGL&#41;&#44; Abi&#225;n Montesdeoca Meli&#225;n &#40;AMM&#41;&#44; Marisa Navarro G&#243;mez &#40;MLNG&#41;&#44; Valent&#237;n Pineda Solas &#40;VPS&#41;&#44; Irene Rivero Calle &#40;IRC&#41;&#44; Jes&#250;s Ruiz-Contreras &#40;JRC&#41; and Pepe Serrano Marchuet &#40;PSM&#41;&#46;</p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Members of the Advisory Committee on Vaccines of the Asociaci&#243;n Espa&#241;ola De Pediatr&#237;a"
            "identificador" => "sec0160"
          ]
        ]
      ]
    ]
    "multimedia" => array:34 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Adapted from the American Academy of Pediatrics Red Book 2023&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">High-level immunosuppression<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Inborn errors of immunity involving B and T cells&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Chemotherapy and&#47;or radiotherapy in the past 6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; HSCT recipients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; CAR-T cell therapy recipients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Solid organ transplant recipients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Chronic renal insufficiency&#46; Renal replacement therapy &#40;haemodialysis and peritoneal dialysis&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; HIV infection with CD4 count &#60;200 cells&#47;mm<span class="elsevierStyleSup">3</span> in patients aged &#8805;14 years or CD4 percentage &#60;15&#37; in patients aged &#60;13 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Treatment con&#58; azathioprine &#62;3&#8239;mg&#47;kg&#47;day&#44; 6-mercaptopurine &#62;1&#46;5&#8239;mg&#47;kg&#47;day&#44; methotrexate &#62;0&#46;4&#8239;mg&#47;kg&#47;week or &#8805;15&#8239;mg&#47;m<span class="elsevierStyleSup">2</span>&#47;week or &#8805;25&#8239;mg&#47;week&#44; leflunomide &#8805;0&#46;5&#8239;mg&#47;kg&#47;day or &#62;20&#8239;mg&#47;week&#44; ciclosporin &#62;2&#46;5&#8239;mg&#47;kg&#47;day&#44; mycophenolate mofetil &#8805;30&#8239;mg&#47;kg&#47;day or &#62;1000&#8239;mg&#47;day&#44; cyclophosphamide oral &#62;2&#8239;mg&#47;kg&#47;day&#44; tacrolimus &#62;1&#46;5&#8239;mg&#47;day&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Steroid therapy<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#58; systemic treatment with prednisone &#40;or dose equivalent&#41;&#58; &#8805;2&#8239;mg&#47;kg&#47;day for &#8805;14 days&#59; &#8805;1&#8239;mg&#47;kg&#47;day for &#8805;28 days&#59; &#8805;20&#8239;mg&#47;day in patients weighing more than 10&#8239;kg for &#8805;14 days&#46; Intravenous methylprednisolone&#44; bolus &#8805;500&#8239;mg&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Immunosuppressive monoclonal antibodies &#40;MABs&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> and other biologic agents&#58; anti-TNF-&#945; infliximab&#44; adalimumab&#44; certolizumab&#44; etanercept and golimumab &#41;&#44; B cell depletion therapy &#40;rituximab&#41;&#44; T cell depletion therapy &#40;alemtuzumab&#41;&#44; interleukin inhibitors including IL-6R &#40;sarilumab&#44; tocilizumab&#41;&#44; IL-17A &#40;secukinumab&#41;&#44; IL-12&#47;23 &#40;ustekinumab&#41;&#44; IL-23 &#40;guselkumab&#41;&#44; IL-1 &#40;canakinumab&#41;&#44; IL-1R &#40;anakinra&#41;&#44; IL-4&#47;13 &#40;dupilumab&#41;&#44; IL-5 &#40;mepolizumab&#41; and anti-B-cell activating factor &#40;BLyS&#44; belimumab&#41;&#46; Janus kinase &#40;JAK&#41; inhibitors&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Combination therapy&#44; independently of the dose&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401256.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Low-level immunosuppression&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Asymptomatic HIV infection with CD4 count &#8805;200 cells&#47;mm<span class="elsevierStyleSup">3</span> in patients aged &#8805;14 years&#44; or a CD4 percentage &#8805;15&#37; in patients aged &#60;13 years&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Steroid therapy &#8805;14 days with a single dose&#47;day below the dose that produces high-level immunosuppression or patients receiving steroids on alternating days&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>&#8226; Methotrexate at a dose &#8804;0&#46;4&#8239;mg&#47;kg&#47;week or &#60;15&#8239;mg&#47;m<span class="elsevierStyleSup">2</span>&#47;week&#44; azathioprine at a dose &#8804;3&#8239;mg&#47;kg&#47;day or 6-mercaptopurine at a dose &#8804;1&#46;5&#8239;mg&#47;kg&#47;day&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401257.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Live attenuated vaccines are contraindicated in patients with high-level immunosuppression&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Steroid therapy&#58; treatments lasting &#60;2 weeks &#40;except boluses&#41;&#44; lower doses&#44; replacement therapy at physiological doses&#44; topical treatment&#44; or inhaled or intra-articular steroid administration are not a contraindication for administration of live attenuated vaccines&#46; The interval required after high-level immunosuppressive therapy for the administration of attenuated vaccines is 1 month&#44; and 3 months after a bolus&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Immunosuppressive MABs&#58; administer vaccines before treatment initiation&#44; at least 2 weeks before for inactivated vaccines and 4 weeks before for attenuated vaccines 4 weeks &#40;6 weeks before treatment with alemtuzumab&#41;&#46; During treatment&#44; if administration of an inactivated vaccine is necessary&#44; it is best to administer it a few days before the next MAB dose&#44; and attenuated vaccines are contraindicated&#44; although their administration can be contemplated on a case-by-case basis in stable patients receiving maintenance immunosuppressive therapy &#40;section 5&#41;&#46; After treatment completion&#44; the recommended interval before vaccine administration is of 5 times the plasma half-time of the drug&#44; which amounts to 3&#8211;6 months after treatment with anti-TNF&#945; or anti-interleukin antibodies&#44; and 12 months following B cell depletion&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Classification of immunodeficiencies based on the extent of immunosuppression&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0010"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">IMD&#44; invasive meningococcal disease&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Depending on age at start of vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Schedule in immunosuppressed individuals&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Comments<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hexavalent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 weeks</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Schedule</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Consider booster doses on a case -by-case basis</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">DTaP-IPV<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">b</span></a>&#44; Tdap-IPV<a class="elsevierStyleCrossRef" href="#tblfn0025"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PCV 15&#47;20</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 week&#8211;11 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">3&#8239;&#43;&#8239;1</span> &#40;at 2&#44; 4&#44; 6 and 11 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All children and adolescents with immunodeficiency&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#8722;2 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">2&#47;3 doses</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PCV15&#8239;&#43;&#8239;PPSV23 or PCV20 alone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;5 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">2 doses</span> &#40;at least 2 months apart&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Unvaccinated &#8805;6 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">1 dose</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">PPSV23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;2 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">2 doses</span> &#40;5 years apart&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MenB&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Schedule depends on age at first dose&#8239;&#43;&#8239;1 dose 1 year after completion of primary series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster every 5 years in patients at risk of IMD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MenACWY</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;6 weeks or &#62;1&#8722;2 years depending on the preparation</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">2 doses</span> &#40;interval&#44; 8 weeks&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster every 5 years in patients with asplenia&#44; complement&#44; properdin or factor D deficiency or treated with eculizumab or ravulizumab</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster at 3 years in patients &#60;7 years and every 5 years in patients &#62;7 years if risk persists&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HPV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;9 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">3 doses</span> &#40;0&#44; 1&#8722;2 and 6 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses&#44; independently of age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hib</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 weeks</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;12 months schedule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster depending on the situation</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&#8722;59 months 2 <span class="elsevierStyleBold">doses</span> &#40;0&#8722;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">1 dose</span> in patients &#62;5 years independently of previous vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Influenza<a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Age &#60;9 years&#58; <span class="elsevierStyleBold">2 doses</span> 4 weeks apart the first year&#44; &#62;9 years&#58; <span class="elsevierStyleBold">1 dose</span> yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SARS-CoV-2</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;6 months</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&#8239;-&#8239;5 years <span class="elsevierStyleBold">3</span> doses &#40;0&#8722;3&#8211;8 weeks&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Schedule set for Autumn 2023&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8211;12 years <span class="elsevierStyleBold">2&#8239;&#43;&#8239;1</span> &#40;3 weeks between doses 1 and 2&#59; &#8805;8 sem&#46; between doses 2 and 3&#41;&#8239;&#43;&#8239;<span class="elsevierStyleBold">booster</span> at 3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 booster dose independently of number of previous doses &#40;including no previous dose&#41;&#46;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;12 years <span class="elsevierStyleBold">2&#8239;&#43;&#8239;1</span> &#40;3 weeks between doses 1 and 2&#59; &#8805;4 weeks between doses 2 and 3&#41;&#8239;<span class="elsevierStyleBold">&#43;&#8239;booster</span> at 3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HB<a class="elsevierStyleCrossRef" href="#tblfn0035"><span class="elsevierStyleSup">d</span></a></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neonatal period</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">0&#44; 1 and 6 months&#44;</span> if response &#60;10&#8239;IU&#47;mL&#44; repeat full series</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Accelerated schedule&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44; 7 and 21 days&#59; 0&#44; 10&#44; 21 days and 0&#44; 1 and 2 months&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">In accelerated schedules&#44; 1 dose must be given at 12 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HA<a class="elsevierStyleCrossRef" href="#tblfn0040"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;12 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">0 and 6&#8722;12 months&#44;</span> if response &#60;10&#8239;IU&#47;mL&#44; repeat full series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">An accelerated schedule is possible if administered in combination with hepatitis B&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">MMR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doses given at 6&#8722;11 months do not count for primary series <span class="elsevierStyleBold">&#62;</span>11 months <span class="elsevierStyleBold">2 doses</span> &#40;4 weeks apart&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Contraindicated</span> from 4 weeks before immunodepression and for 6&#8722;24 months after&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">VZV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;12 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">2 doses</span> &#40;4 weeks apart&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster depending on serologic status &#40;single dose&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401258.png"
              ]
            ]
          ]
          "notaPie" => array:5 [
            0 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Inactivated vaccines should be given at least 2 weeks before initiation of immunosuppressive therapy and 3&#8722;6 months after its completion&#46; Attenuated vaccines should be given at least 4 weeks before initiation of immunosuppressive therapy and 3&#8211;24 months after its completion and are contraindicated during treatment&#46; Besides the booster doses generally recommended for immunosuppressed patients&#44; necessary booster doses vary depending on the risk group&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0025">DTaP&#58; the full-dose toxoid vaccine is recommended by some authors regardless of age in immunosuppressed patients&#44; such as HSCT recipients&#46; Hexavalent vaccines are authorised for catch-up vaccination following immunosuppressive therapy independently of age&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0030"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0030">Influenza&#58; consider additional doses in situations in which the circulating strain is very different from those of previous seasons&#44; independently of vaccination status&#46; The intranasal live attenuated influenza vaccine is contraindicated&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0035"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0035">HB&#46; In patients with a poor response &#40;anti-HB antibodies &#8804;10&#8239;mUI&#47;mL&#41;&#44; revaccinate with another 3 doses &#40;at 0&#44; 1 and 6 months&#41;&#46; In patient &#62;15 years&#44; consider using the high-dose or adjuvanted vaccine&#46; If anti-HB antibodies remain &#8804;10&#8239;mUI&#47;mL after revaccination&#44; the patient is considered a non-respondent and should receive specific immunoglobulin in the case of exposure&#46;</p>"
            ]
            4 => array:3 [
              "identificador" => "tblfn0040"
              "etiqueta" => "e"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0040">HA&#46; Revaccinate with 2 doses if the IgG level&#8239;&#60;&#8239;10&#8239;mIU&#47;mL after the HA primary vaccination series&#46; Antibody levels should be measured 1&#8211;2 months after&#44; and if they are poor &#40;&#60;10&#8239;mIU&#47;mL&#41;&#44; additional vaccination is not recommended&#44; and education should be provided on how to avoid infection&#44; including the need to receive polyvalent immunoglobulins after exposure&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">General recommendations for vaccination of immunosuppressed children and adolescents&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0015"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">post-HSCT interval&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Number of doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Diphtheria&#44; tetanus&#44; pertussis</span><a class="elsevierStyleCrossRefs" href="#tblfn0045"><span class="elsevierStyleSup">a&#44;b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 or 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">IPV</span><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 or 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">PCV</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Meningococcal ACWY</span><a class="elsevierStyleCrossRef" href="#tblfn0055"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Meningococcal B</span><a class="elsevierStyleCrossRef" href="#tblfn0060"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 or 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">HPV</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hib</span><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 or 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Inactivated influenza</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#8722;6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 or 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">SARS-CoV-2</span><a class="elsevierStyleCrossRef" href="#tblfn0065"><span class="elsevierStyleSup">e</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8722;6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hepatitis B</span><a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hepatitis A</span><a class="elsevierStyleCrossRef" href="#tblfn0070"><span class="elsevierStyleSup">f</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Measles&#44; mumps&#44; rubella</span><a class="elsevierStyleCrossRef" href="#tblfn0075"><span class="elsevierStyleSup">g</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Varicella</span><a class="elsevierStyleCrossRef" href="#tblfn0075"><span class="elsevierStyleSup">g</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401255.png"
              ]
            ]
          ]
          "notaPie" => array:7 [
            0 => array:3 [
              "identificador" => "tblfn0045"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0045">Hexavalent vaccines can be used at any age to give fewer shots&#44; always with the prior consent of the family&#46; Doses should be given at least 1 month apart&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0050"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0050">DTaP is preferred for any age&#44; although Tdap may be used in patients aged more than 7 years&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0055"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0055">The two doses should be given at least 8 weeks apart&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0060"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0060">Schedule based on age&#46; See recommendations of the Ministry of Health&#46;</p>"
            ]
            4 => array:3 [
              "identificador" => "tblfn0065"
              "etiqueta" => "e"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0065">According to the recommendations of the Ministry of Health&#44; always considering these patients a risk group for the purposes of administering additional doses&#46;</p>"
            ]
            5 => array:3 [
              "identificador" => "tblfn0070"
              "etiqueta" => "f"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0070">Only in patients with liver disease or relevant risk factors&#46;</p>"
            ]
            6 => array:3 [
              "identificador" => "tblfn0075"
              "etiqueta" => "g"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0075">If not receiving immunosuppressive therapy&#44; at least 3 months before&#44; and is not receiving immunoglobulin therapy and has a CD4 count &#62;200 cells&#47;mm<span class="elsevierStyleSup">3</span>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Vaccines&#44; interval to vaccination following HSCT and number of doses needed&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0020"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaccination before solid organ transplantation &#40;SOT&#41;</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Complete vaccination pre-SOT<a class="elsevierStyleCrossRef" href="#tblfn0080"><span class="elsevierStyleSup">a</span></a></th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Incomplete vaccination pre SOT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">No pre-SOT vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Received doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Doses to administer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Doses to administer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Doses to administer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hepatitis B</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;at 0&#44; 1&#44; 6 months&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Based on serologic status&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses &#40;at 0&#44; 1&#44; 6 months&#41;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- If anti-HBcs antibodies are negative post SOT <elsevierMultimedia ident="202312211250278021"></elsevierMultimedia>&#58; full series&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- If anti-HBcs &#62;10&#8239;IU&#47;L <elsevierMultimedia ident="202312211250278022"></elsevierMultimedia>&#58; none required&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hepatitis A</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;at 0&#44;6 months&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Based on serologic status&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 doses &#40;at 0&#44; 6 months&#41;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- If HA IgG test is positive&#44; none required&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- If HA IgG test is negative&#44; full series&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IPV</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;24 months&#58; 3 doses &#40;at 0&#44; 2&#44; 8 months&#41; and continue vaccination according to standard schedule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 months&#8211;6 years&#58; 4 doses &#40;at 0&#44; 2&#44; 8 and 14 months&#41; and continue vaccination according to standard schedule for age 7&#8722;18 years&#58; 3 doses &#40;at 0&#44; 2&#44; 8 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">DTaP&#47;Tdap &#40;depending on age&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8805;4</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;administer 1 dose de Tdap every 10 years&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;24 months&#58; 3 doses &#40;at 0&#44; 2&#44; 8 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;5 years&#58; 3 doses &#40;at 0&#44; 2&#44; 8 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#8211;11&#8239;years&#58; 4 doses &#40; at 0&#44; 2&#44; 8&#44; 14 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&#8211;18 years&#58; 5 doses of Tdap &#40;at 0&#44; 2&#44; 8&#44; 14&#44; 20 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses if age &#60;5 years &#40;at 0&#44; 2&#44; 8 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Meningococcal B<a class="elsevierStyleCrossRef" href="#tblfn0085"><span class="elsevierStyleSup">b</span></a></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#47;3</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;2 years&#58; 3 doses &#40;at 0&#44; 2&#44; 6 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8211;18 years&#58; 2 doses &#40;at 0&#44; 2 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Meningococcal C<a class="elsevierStyleCrossRef" href="#tblfn0090"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">If the patient has received 1 dose of MenC &#40;pre SOT&#41;&#44; 2 doses of MenACWY</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vaccination with 2 doses of MenACWY &#40;at 0&#44; 2 months&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Meningococcal ACWY<a class="elsevierStyleCrossRef" href="#tblfn0090"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 doses &#40;at 0&#44; 2 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7-valent pneumococcal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 dose of PCV15&#8239;&#43;&#8239;2 doses of PPSV23 &#40;2 months after the last dose of PCV15&#44; from 2 years of age&#44; and 5 years after the first dose of PPSV23&#41; or 1 dose of PCV20</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination with PCV15 followed by 2 doses of PPSV23 &#40;2 months from the last PCV13 dose&#44; from 2 years of age&#44; and 5 years after the first dose of PPSV23&#41; or completion of series with PCV20</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13-valent pneumococcal &#40;Prevenar13&#44; PCV13&#41; or 15-valent pneumococcal &#40;PCV15&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;24 months&#58; 3 doses of PCV15&#47;20 &#40;at 0&#44; 2&#44; 4 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23-valent pneumococcal polysaccharide &#40;PPSV23&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24 months-6 years&#58; 2 doses of PCV15&#47;20 &#40;at 0&#44; 2 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#8722;18 years&#58; 1 dose of PCV15&#8239;&#43;&#8239;2 doses of PPSV23&#58; 2 months from the last PCV15 dose and 5 years later&#41; or 1 dose of PCV20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HPV<a class="elsevierStyleCrossRef" href="#tblfn0095"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 or 3 &#40;based on vaccine used and age at start of vaccination&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;in patients who have received 2 doses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complete vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses &#40;at 0&#44; 2&#44;6 months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Seasonal influenza&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Yearly&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Measles&#44; mumps&#44; rubella&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Varicella&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401263.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0080"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0080">Current standard schedule recommended for primary vaccination of children&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0085"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0085">Vaccination against meningococcal B disease is considered complete with a 3-dose series if primary vaccination was initiated before age 24 months&#44; as long as the last dose was administered 12 months after&#44; and considered complete with 2 doses if the primary series started after age 24 months&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0090"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0090">In the case of the conjugate vaccine against meningococcal C disease and the vaccine against groups A&#44; C&#44; W and Y&#58; 1 dose of MenC at 4 months&#44; MenC&#47;MenACWY at 12 months and MenACWY at 12&#8211;14 years&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0095"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0095">Vaccination against human papillomavirus is indicated for both sexes&#44; preferably with 9-valent vaccine&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Vaccines&#44; required number of doses and intervals based on complete or incomplete vaccination status before solid organ transplantation&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0025"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Innate error of immunity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaccines that are contraindicated or should not be administered&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Indicated vaccines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Comments&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cellular immunodeficiencies&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All live attenuated vaccines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Expanded vaccination against encapsulated bacteria &#40;pneumococcus&#44; meningococcus &#91;B&#47;ACWY&#93; and Hib&#41;&#44; in addition to the SARS-COV-2 vaccine and the annual inactivated influenza vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Most guidelines recommend administration of all inactivated vaccines included in the routine vaccination schedule&#44; while others do not recommend it &#40;with the exception of the influenza vaccine&#41; if the patient is receiving treatment with immune globulins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Major antibody deficiency &#40;pure B cell disorders&#41;&#58; X-linked agammaglobulinaemia&#44; common variable immunodeficiency&#44; activated PI3K delta syndrome &#40;APDS&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All live vaccines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Expanded vaccination against encapsulated bacteria &#40;meningococcus and pneumococcus<a class="elsevierStyleCrossRef" href="#tblfn0100"><span class="elsevierStyleSup">a</span></a>&#41;&#44; and vaccination against SARS-COV-2 and annual vaccination against influenza with inactivated vaccine Other inactivated vaccines in the routine schedule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">The rotavirus vaccine can be given The MMR and varicella vaccines are not necessary if the patient receives immune globulins&#44; as they would provide passive immunization against these infections and could interfere with the immune response to the vaccine&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Minor antibody deficiency&#58; IgA deficiency&#44; IgG subclass deficiency&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Oral poliovirus vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All vaccines in the routine schedule&#44; including the MMR and varicella vaccines&#46; Annual vaccination against influenza&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">If the patient has frequent respiratory symptoms&#44; administration of the pneumococcal conjugate vaccine is recommended &#40;PCV15 or 20&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Combined T and B cell or syndromic immunodeficiencies&#58; Di George syndrome&#44; ataxia-telangiectasia&#44; Wiskott&#8211;Aldrich syndrome&#44; hyper-IgE syndrome&#44; hyper-IgM syndrome&#44; chronic mucocutaneous candidiasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Expanded vaccination against encapsulated bacteria &#40;pneumococcus&#44; meningococcus &#91;B&#47;ACWY&#93; and Hib&#41;&#44; in addition to the SARS-COV-2 vaccine and the annual inactivated influenza vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">May receive live attenuated viral vaccines if CD4 count &#8805;500 cells&#47;mm<span class="elsevierStyleSup">3</span> &#40;&#62;1000 in children aged 1&#8722;6 years&#59; 1500 in infants &#60;1 year&#41; and CD8 count &#8805;200 cells&#47;mm<span class="elsevierStyleSup">3</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complement deficiencies&#58; late common pathway&#44; properdin or factor D deficiency</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All vaccines in the routine schedule&#44; including the MMR and varicella vaccines&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vaccination with 1 dose of Hib is recommended in previously unvaccinated children aged &#62;5 years&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Must receive expanded vaccination against encapsulated bacteria &#40;pneumococcus meningococcus &#91;B&#47;ACWY&#44; considering revaccination every 3&#8722;5 years&#93; and Hib&#41;&#44; in addition to the SARS-COV-2 vaccine and the annual inactivated influenza vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Consider other measures&#44; such as antibiotic prophylaxis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disorders of phagocyte number or function&#58; chronic granulomatous disease &#40;CGD&#41;&#44; adhesion molecule defects such as leukocyte adhesion deficiency &#40;LAD&#41;&#44; Chediak&#8211;Higashi syndrome&#44; congenital neutropenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Live bacterial vaccines &#40;BCG and oral attenuated typhoid fever vaccine&#41;&#46; Live viral vaccines are contraindicated in LAD and S&#46; de Chediak&#8211;Higashi&#44; but not in CGD or congenital neutropenia &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All vaccines in the routine schedule save for the MMR and varicella vaccines in patients with LAD or Chediak&#8211;Higashi syndrome&#44; in whom they are contraindicated&#46; Vaccination against influenza is a must&#44; as influenza increases the risk of infection by <span class="elsevierStyleItalic">S&#46; aureus</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vaccination against pneumococcal disease with con PCV15&#8239;&#43;&#8239;PPSV23 or PCV20 alone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Innate immune defects&#58; &#40;defects of the IL-12 axis&#47;interferon gamma&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All live attenuated vaccines&#44; bacterial &#40;BCG and oral attenuated typhoid fever vaccine&#41; or viral &#40;MMR and varicella&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All vaccines in the routine schedule save for live attenuated vaccines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vaccination against pneumococcal disease with con PCV15&#8239;&#43;&#8239;PPSV23 or PCV20 alone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Innate immune defects&#58; &#40;IRAK4 and MyD88 deficiency&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">All vaccines in the routine schedule&#46; Vaccination against pneumococcal disease with con PCV15&#8239;&#43;&#8239;PPSV23 or PCV20 alone&#44; and vaccination against SARS-COV-2 and annual vaccination against influenza&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401254.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0100"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0100">Expanded vaccination against encapsulated bacteria&#58; <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b&#44; pneumococcus and all meningococcal serogroups &#40;B&#47;ACWY&#41;&#46; At the start of immunization in the early months of life&#44; the patient should always be vaccinated with pneumococcal conjugate vaccine in a 3&#8239;&#43;&#8239;1 schedule&#44; with the additional use of PPSV23 in children aged more than 2 years&#44; if the PCV15 was given&#44; and at least 8 weeks apart from the last administered dose&#44; or else administering the PCV20&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Vaccination in the most frequent inborn errors of immunity&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0030"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">HA&#44; hepatitis A&#59; vaccine HB&#44; hepatitis B vaccine&#59; HPV&#44; human papillomavirus vaccine&#59; Tdap&#44; reduced toxoid tetanus&#44; diphtheria and acellular pertussis vaccine&#59; VZV&#44; varicella zoster vaccine&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Vaccine&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Cardiovascular and respiratory diseases<a class="elsevierStyleCrossRef" href="#tblfn0105"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Renal diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Liver diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Neurologic diseases&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tdap&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278023"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278024"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278025"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278026"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pneumococcal<a class="elsevierStyleCrossRef" href="#tblfn0110"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278027"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278028"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="202312211250278029"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780210"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">VZV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780211"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780212"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780213"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HB<a class="elsevierStyleCrossRef" href="#tblfn0115"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780214"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780215"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HA<a class="elsevierStyleCrossRef" href="#tblfn0120"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780216"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780217"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780218"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Influenza&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780219"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780220"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780221"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780222"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SARS-CoV-2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780223"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780224"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780225"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><elsevierMultimedia ident="2023122112502780226"></elsevierMultimedia>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401259.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0105"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0105">Including children with cyanotic congenital heart disease&#44; heart disease manifesting with heart failure or haemodynamic instability&#44; pulmonary hypertension&#44; bronchopulmonary dysplasia&#44; cystic fibrosis&#44; bronchiectasis and asthma with a high risk of exacerbation&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0110"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0110">Conjugated vaccine &#40;PCV20 or PCV15&#41; followed by 1 dose of PPSV23 and a booster at 5 years in children aged &#62;2 years at high risk&#44; such as children with asplenia&#44; a cochlear implant&#44; loss of cerebrospinal fluid&#44; heart disease&#44; diabetes&#44; liver disease&#44; chronic pulmonary disease or receiving immunosuppressive treatment&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0115"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0115">Monitoring the vaccine response is particularly important in patients with liver disease&#46; If the post-vaccine level of anti-HB is &#60;10&#8239;mIU&#47;mL&#44; the full series should be administered again &#40;0&#44; 1 and 6 months&#41;&#59; if the antibody screen continues to be negative&#44; the patient should be considered a non-respondent&#44; and no further doses should be given&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0120"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0120">The standard schedule may be applied from age 12 months &#40;doses at 0 and 6 months&#41;&#44; or the combination vaccine &#40;A&#8239;&#43;&#8239;B&#58; 3 doses&#41; if the patient requires a booster dose of HB&#46; Recommended for patients receiving hepatotoxic treatment&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Vaccines specifically recommended for different chronic diseases&#46;</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0035"
        "etiqueta" => "Table 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0035"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">ID&#44; intradermal&#59; IM&#44; intramuscular&#59; O&#44; oral&#59; SC&#44; subcutaneous&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Required vaccines</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Schedule&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Comments&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Yellow fever &#40;SC&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 9 months</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Single dose</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">It may be required to enter certain countries&#44; according to the international travel and health guidance of the WHO&#46; In situations in which it is not possible to give the child a mandatory vaccine&#44; a medical exemption certificate must be obtained&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">This vaccine is contraindicated in children with severe egg allergy&#44; immunosuppression and with HIV infection and a CD4 count &#60;200 cells&#47;mL&#46;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">MenACWY &#40;IM&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- Nimenrix&#58; from 6 weeks of life&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;12 months&#58; 2 doses 2 months apart and booster from 12 months&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Required by Saudi Arabia for pilgrims traveling to Mecca for Hajj and Umrah&#44; even if they have been vaccinated against meningococcus group C in the past&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- Menquadfi&#58; from 12 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Single dose from 12 months&#46; Two doses in patients with complement defects&#44; asplenia&#44; TPH and HIV&#44; booster dose every 5 years</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Also required by other countries&#44; such as USA&#44; Canada or the United States&#44; for individuals traveling to study in the country&#46;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">- Menveo&#58; from 2 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Poliovirus &#40;inactivated&#41; &#40;IM&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 6 weeks of life&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses<a class="elsevierStyleCrossRef" href="#tblfn0125"><span class="elsevierStyleSup">a</span></a>&#44; every 1&#8722;2 months&#44; booster 1 year after the third dose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">For travel longer than 4 weeks and travellers to Afghanistan and Pakistan&#44; administration of the oral bivalent or inactivated poliovirus vaccine at least 1 month and no more than 12 months before travel&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401261.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recommended vaccines</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cholera &#40;VO&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 2 years</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&#41; Inactivated&#46; 2&#8722;3 doses&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exceptional indication for travellers to areas with current outbreaks or highly endemic&#44; such as Benin&#44; Burundi&#44; Cameroon&#44; Democratic Republic of the Congo&#44; Ethiopia&#44; Kenia&#44; Malawi&#44; Mozambique&#44; Nigeria&#44; Somalia&#44; Sudan&#44; Uganda&#44; Bangladesh&#44; India&#44; Yemen&#44; Haiti and Philippines</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;6 years&#58; 3 doses&#46; Booster at 6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;6 years&#58; 2 doses&#46; Booster at 2 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&#41; Attenuated&#46; 1 dose&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8722;6 years&#58; 1 dose de 50&#8239;mL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62;6 years&#58; 1 dose de 100&#8239;mL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Central European encephalitis &#40;IM&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 12 months</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 doses &#40;0&#44; 1&#8722;3 months and 6&#8722;15 months&#41;&#46; Booster every 5 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Travellers to risk areas with stays longer than 3&#8722;4 weeks in wooded areas of Russia and Northeastern and Central Europe &#40;especially Lithuania&#44; Czech Republic&#44; Germany and Sweden&#41;&#46;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Accelerated schedule&#58; 0&#44; 7&#44; 21 days&#44; or else 0&#44; 14 days&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster 12&#8722;18 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Japanese encephalitis &#40;IM&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 2 months of age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 doses at days 0 and 28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Travellers who are going to spend long periods out of doors &#40;camping&#44; hiking&#41; in rural areas with endemic transmission during the rainy season&#44; chiefly in Japan&#44; Southeast Asia and the Western Pacific region&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Typhoid fever</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&#41; From 2 years of age</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&#41; Single dose&#46; Booster every 2&#8722;3 years</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Travel to areas of North and West Africa&#44; South Asia&#44; Indonesia and Peru</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">A&#41; IM</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">B&#41; VO</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&#41; From 6 years &#40;in summary of product characteristics&#44; 3 years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&#41; 3 doses&#46; 3 capsules taken in alternating days on an empty stomach&#46; Revaccinate every 1&#8722;3 years if the risk persists&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hepatitis A &#40;IM&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 12 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 doses&#58; 0 and 6&#8722;12 months</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">In patients at risk&#44; it can be given from 6 months&#44; but the does not count toward the routine vaccine series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead rowgroup " rowspan="10" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Rabies &#40;IM and ID&#41;</span></td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="10" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Do not give to children under 1 year for prevention&#44; but give for prophylaxis if there is risk due to a bite</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De 2 a 6 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="10" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Children who are to travel for prolonged stays to endemic areas&#44; especially remote areas or going to caves&#44; where treatment with immune globulin may be difficult to access</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Pre-exposure course&#58;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ID&#58; 0<span class="elsevierStyleSup">2</span>&#44; 7<span class="elsevierStyleSup">2</span> and 28<span class="elsevierStyleSup">2</span><a class="elsevierStyleCrossRef" href="#tblfn0130"><span class="elsevierStyleSup">b</span></a>&#44; 4 or 6 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&#58; 0&#44; 7 and 28<a class="elsevierStyleCrossRef" href="#tblfn0130"><span class="elsevierStyleSup">b</span></a> days&#44; 2 or 3 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Booster in 2&#8722;5 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Post-exposure course&#58;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;&#43;Human rabies immune globulin&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ID&#58; 0&#44; 3 and 7 at 2 sites&#44; 6 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&#58; 0&#44; 3&#44; 7 and 21&#44; 4 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">IM&#58; 0 at 2 sites&#44; 7 and 21&#44; 4 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dengue &#40;SC&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From 4 years of age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 doses&#58; 0 and 3 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated in patients with history of anaphylaxis to any component&#44; immunodeficiencies&#44; pregnant or breastfeeding women&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tuberculosis &#40;ID&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">From birth&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Single dose&#58; 0&#46;1&#8239;mL in infants &#62;1 year and 0&#46;05&#8239;mL in children &#60;1 year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Can be considered in previously unvaccinated individuals with a negative Mantoux test depending on the destination and nature of the trip&#46; Contraindicated in children &#60;2 years who are household contacts of a suspected or confirmed case of active tuberculosis&#44; HIV&#8239;&#43;&#8239;individual&#44; infants born to mothers who received immunosuppressive biologic agents during pregnancy and&#47;or individuals currently receiving or who have received treatments affecting immunity in the past 6 months &#40;chemotherapy&#44; radiotherapy or biologic agents&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401260.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0125"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0125">There are combination vaccines against diphtheria&#44; tetanus&#44; pertussis and <span class="elsevierStyleItalic">Haemophilus influenzae</span> type b&#44; with or without a hepatitis B component&#44; that in principle are indicated for primary vaccination in children&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0130"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0130">This additional dose only applies to immunosuppressed patients&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Specific vaccines for travellers&#58; required and recommended depending on the travel plan&#46;</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0040"
        "etiqueta" => "Table 8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0040"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">X&#58; same as vaccination recommended in healthy children&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HIV with CD4&#8239;&#62;&#8239;200&#47;mm<span class="elsevierStyleSup">3</span><a class="elsevierStyleCrossRef" href="#tblfn0135"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HIV&#47;AIDS&#44; CD4&#8239;&#60;&#8239;200&#47;mm<span class="elsevierStyleSup">3</span><a class="elsevierStyleCrossRef" href="#tblfn0140"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Severe&#44; non-HIV immunosuppressed status<a class="elsevierStyleCrossRef" href="#tblfn0145"><span class="elsevierStyleSup">c</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Chronic disease<a class="elsevierStyleCrossRef" href="#tblfn0150"><span class="elsevierStyleSup">d</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">BCG</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">MMR</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">With caution or recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated or with caution&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Typhoid fever &#40;VO&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Typhoid fever &#40;IM&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Yellow fever</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">With caution&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicated&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Japanese encephalitis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Central European encephalitis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Rabies</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Cholera</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Hepatitis A</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Meningococcal&#44; PCV 15&#47;20&#44; PPSV23</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">X&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Influenza</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Recommended&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3401262.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "tblfn0135"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0135"><span class="elsevierStyleItalic">HIV and CD4&#8239;&#62;&#8239;200&#47;mm</span><span class="elsevierStyleSup">3</span>&#46; Live attenuated vaccines should not be administered&#44; with the exception of the MMR and varicella vaccines if the CD4 count &#62;200&#46; The response to inactivated vaccines may be suboptimal&#46; Postponing travel &#40;and therefore vaccination&#41; for at least 3 months after immune reconstitution is recommended&#46; Despite lower rates of seroconversion and antibody titres compared to healthy children&#44; these patients respond with protective antibodies to most studied vaccines&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0140"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0140"><span class="elsevierStyleItalic">HIV&#47;AIDS with CD4&#8239;&#60;&#8239;200&#47;mm</span><span class="elsevierStyleSup">3</span>&#46; In children with HIV&#44; it is essential to know the CD4 count before travel&#46; If the CD4 count is &#60;200&#47;mm<span class="elsevierStyleSup">3</span> and the patient is not receiving antiretroviral treatment&#44; travel must be deferred until antiretroviral therapy is initiated and immune reconstitution achieved&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0145"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0145"><span class="elsevierStyleItalic">Severe non-HIV immunosuppression</span>&#46; Includes&#58; patients with active leukaemia or lymphoma&#44; generalised cancer&#44; aplastic anaemia&#44; graft-versus-host disease&#44; inborn errors of immunity&#44; current or very recent radiation therapy&#44; first two years after solid organ or haematopoietic stem cell transplantation&#44; or transplant recipients more than 2 years post transplantation&#44; receiving immunosuppressive therapy&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "tblfn0150"
              "etiqueta" => "d"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0150"><span class="elsevierStyleItalic">Chronic diseases associated with limited immunodeficiency</span>&#46; Including&#58; asplenia&#44; chronic renal or liver disease&#44; diabetes or complement deficiency&#46; Asplenic patients are at greater risk of infection and disease by encapsulated bacteria&#44; and while the vaccine response may be suboptimal&#44; it is important to ensure they are correctly vaccinated against meningococcal disease &#40;ABCWY&#41;&#44; pneumococcal disease and Hib&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Specific recommendations for vaccination of immunosuppressed children who are travelling&#46;</p>"
        ]
      ]
      8 => array:5 [
        "identificador" => "202312211250278021"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 21
            "Ancho" => 32
            "Tamanyo" => 590
          ]
        ]
      ]
      9 => array:5 [
        "identificador" => "202312211250278022"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 21
            "Ancho" => 32
            "Tamanyo" => 590
          ]
        ]
      ]
      10 => array:5 [
        "identificador" => "202312211250278023"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      11 => array:5 [
        "identificador" => "202312211250278024"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      12 => array:5 [
        "identificador" => "202312211250278025"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      13 => array:5 [
        "identificador" => "202312211250278026"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      14 => array:5 [
        "identificador" => "202312211250278027"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      15 => array:5 [
        "identificador" => "202312211250278028"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      16 => array:5 [
        "identificador" => "202312211250278029"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      17 => array:5 [
        "identificador" => "2023122112502780210"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      18 => array:5 [
        "identificador" => "2023122112502780211"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      19 => array:5 [
        "identificador" => "2023122112502780212"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      20 => array:5 [
        "identificador" => "2023122112502780213"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      21 => array:5 [
        "identificador" => "2023122112502780214"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      22 => array:5 [
        "identificador" => "2023122112502780215"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      23 => array:5 [
        "identificador" => "2023122112502780216"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      24 => array:5 [
        "identificador" => "2023122112502780217"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      25 => array:5 [
        "identificador" => "2023122112502780218"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      26 => array:5 [
        "identificador" => "2023122112502780219"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      27 => array:5 [
        "identificador" => "2023122112502780220"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      28 => array:5 [
        "identificador" => "2023122112502780221"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      29 => array:5 [
        "identificador" => "2023122112502780222"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      30 => array:5 [
        "identificador" => "2023122112502780223"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      31 => array:5 [
        "identificador" => "2023122112502780224"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      32 => array:5 [
        "identificador" => "2023122112502780225"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
      33 => array:5 [
        "identificador" => "2023122112502780226"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx2.jpeg"
            "Alto" => 40
            "Ancho" => 56
            "Tamanyo" => 667
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:39 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunization and other considerations in immunocompromised children"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "American Academy of Pediatrics"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:1 [
                      "LibroEditado" => array:6 [
                        "editores" => "D&#46;W&#46;Kimberlin, M&#46;T&#46;Brady, M&#46;A&#46;Jackson, S&#46;S&#46;Long"
                        "titulo" => "Red Book&#58; 2021&#8211;2024&#46; Report of the Committee on Infectious Diseases"
                        "paginaInicial" => "72"
                        "paginaFinal" => "84"
                        "edicion" => "32st ed&#46;"
                        "serieFecha" => "2021"
                      ]
                    ]
                    1 => array:1 [
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;www&#46;cdc&#46;gov&#47;vaccines&#47;schedules&#47;downloads&#47;child&#47;0-18yrs-combined-schedule-bw&#46;pdf"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Gu&#237;a de vacunaci&#243;n en pacientes tratados con anticuerpos monoclonales y otros agentes biol&#243;gicos&#58; una revisi&#243;n actualizada"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Sociedad Andaluza de Medicina Preventiva&#44; Salud P&#250;blica y Gesti&#243;n Sanitaria"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:2 [
                        "edicion" => "2 &#170; ed&#46;"
                        "fecha" => "2023"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy&#44; immunogenicity and safety of vaccination in pediatric patients with autoimmune inflammatory rheumatic diseases &#40;pedAIIRD&#41;&#58; a systematic literature review for the 2021 update of the EULAR&#47;PRES recommendations"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;H&#46; Jansen"
                            1 => "C&#46; Rondaan"
                            2 => "G&#46; Legger"
                            3 => "K&#46; Minden"
                            4 => "Y&#46; Uziel"
                            5 => "N&#46; Toplak"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:2 [
                    0 => array:2 [
                      "doi" => "10.3389/fped.2022.910026"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Pediatr"
                        "fecha" => "2022"
                        "volumen" => "10"
                        "paginaInicial" => "910026"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35874582"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                    1 => array:2 [
                      "doi" => "10.3389/fped.2022.910026"
                      "WWW" => array:1 [
                        "link" => "https&#58;&#47;&#47;www&#46;ncbi&#46;nlm&#46;nih&#46;gov&#47;pmc&#47;articles&#47;PMC9298835&#47;"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevalence of immunodeficiency in children with invasive pneumococcal disease in the pneumococcal vaccine era&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "C&#46; Butters"
                            1 => "L&#46;K&#46; Phuong"
                            2 => "T&#46; Cole"
                            3 => "A&#46; Gwee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamapediatrics.2019.3203"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Pediatr"
                        "fecha" => "2019"
                        "volumen" => "173"
                        "paginaInicial" => "1084"
                        "paginaFinal" => "1094"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31566672"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Advances in vaccinating immunocompromised children"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Miller"
                            1 => "K&#46; Leake"
                            2 => "T&#46; Sharma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/MOP.0000000000000846"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Pediatr"
                        "fecha" => "2020"
                        "volumen" => "32"
                        "paginaInicial" => "145"
                        "paginaFinal" => "150"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31790029"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "F&#46; Speth"
                            1 => "C&#46;H&#46; Hinze"
                            2 => "S&#46; Andel"
                            3 => "T&#46; Mertens"
                            4 => "J&#46;P&#46; Haas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s12969-018-0231-3"
                      "Revista" => array:5 [
                        "tituloSerie" => "Pediatr Rheumatol Online J"
                        "fecha" => "2018"
                        "volumen" => "16"
                        "paginaInicial" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29499726"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Comit&#233; Asesor de Vacunas &#40;CAV-AEP&#41;&#46; Vacunaci&#243;n en ni&#241;os inmunodeprimidos o con tratamiento inmunosupresor&#46; Manual de inmunizaciones en l&#237;nea de la AEP&#46; Madrid&#58; AEP&#59; ene&#47;2023 &#91;Accessed el dd&#47;mmm&#47;aaaa&#93;&#46; Available from&#58; <a target="_blank" href="http://vacunasaep.org/documentos/manual/cap-1">http&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-1</a>&#46;"
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Grupo de trabajo vacunaci&#243;n en poblaci&#243;n adulta y grupos de riesgo de la Ponencia de Programa y Registro de Vacunaciones&#46; Vacunaci&#243;n en grupos de riesgo de todas las edades y en determinadas situaciones&#46; Comisi&#243;n de Salud P&#250;blica del Consejo Interterritorial del Sistema Nacional de Salud&#46; Ministerio de Sanidad&#44; Consumo y Bienestar Social&#44; julio 2018&#46;"
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Comit&#233; Asesor de Vacunas &#40;CAV-AEP&#41;&#46; Vacunaci&#243;n de ni&#241;os con trasplante de progenitores hematopoy&#233;ticos y trasplante de &#243;rganos s&#243;lidos&#46; Manual de inmunizaciones en l&#237;nea de la AEP&#46; Madrid&#58; AEP&#59; ene&#47;2023&#46; &#91;Accessed 4 May 2023&#93;&#46; Available from&#58; <a target="_blank" href="http://vacunasaep.org/documentos/manual/cap-16">http&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-16</a>&#46;"
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vaccination of haemopoietic stem cell transplant recipients&#58; guidelines of the 2017 European Conference on Infections in Leukaemia &#40;ECIL 7&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Cordonnier"
                            1 => "S&#46; Einarsdottir"
                            2 => "S&#46; Cesaro"
                            3 => "R&#46; Di Blasi"
                            4 => "M&#46; Mikulska"
                            5 => "C&#46; Rieger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1473-3099(18)30600-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Infect Dis"
                        "fecha" => "2019"
                        "volumen" => "19"
                        "paginaInicial" => "e200"
                        "paginaFinal" => "e212"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30744963"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vaccination of the stem cell transplant recipient and the hematologic malignancy patient"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Kamboj"
                            1 => "M&#46;K&#46; Shah"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Infect Dis Clin N Am"
                        "fecha" => "2019"
                        "volumen" => "33"
                        "paginaInicial" => "593"
                        "paginaFinal" => "609"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "AST Infectious Diseases Community of Practice&#46; Vaccination of solid organ transplant candidates and recipients&#58; guidelines from the American Society of Transplantation Infectious Diseases Community of practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:1 [
                            0 => "L&#46; Danziger-Isakov"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Clin Transplant"
                        "fecha" => "2019"
                        "paginaInicial" => "e13563"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Human inborn errors of immunity&#58; 2022 update on the classification from the International Union of Immunological Societies Expert Committee"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;G&#46; Tangye"
                            1 => "W&#46; Al-Herz"
                            2 => "A&#46; Bousfiha"
                            3 => "C&#46; Cunningham-Rundles"
                            4 => "J&#46;L&#46; Franco"
                            5 => "S&#46;M&#46; Holland"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10875-022-01289-3"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Immunol"
                        "fecha" => "2022"
                        "volumen" => "42"
                        "paginaInicial" => "1473"
                        "paginaFinal" => "1507"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35748970"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The 2022 update of IUIS phenotypical classification for human inborn errors of immunity"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Bousfiha"
                            1 => "A&#46; Moundir"
                            2 => "S&#46;G&#46; Tangye"
                            3 => "C&#46; Picard"
                            4 => "L&#46; Jeddane"
                            5 => "W&#46; Al-Herz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10875-022-01352-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Immunol"
                        "fecha" => "2022"
                        "volumen" => "42"
                        "paginaInicial" => "1508"
                        "paginaFinal" => "1520"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36198931"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "for the Italian Network for Primary Immunodeficiencies &#40;IPINET&#41;&#46; Vaccination in immunocompromised host&#58; recommendations of Italian Primary Immunodeficiency Network Centers &#40;IPINET&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Martire"
                            1 => "C&#46; Azzari"
                            2 => "R&#46; Badolato"
                            3 => "C&#46; Canessa"
                            4 => "E&#46; Cirillo"
                            5 => "V&#46; Gallo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.vaccine.2018.10.056"
                      "Revista" => array:4 [
                        "tituloSerie" => "Vaccine"
                        "fecha" => "2018"
                        "volumen" => "36"
                        "paginaInicial" => "7753"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2013 IDSA clinical practice guideline for vaccination of the immunocompromised host"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L&#46;G&#46; Rubin"
                            1 => "M&#46;J&#46; Levin"
                            2 => "P&#46; Ljungman"
                            3 => "E&#46;G&#46; Davies"
                            4 => "R&#46; Avery"
                            5 => "M&#46; Tomblyn"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/cid/cit684"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clinical Infect Dis"
                        "fecha" => "2014"
                        "volumen" => "58"
                        "paginaInicial" => "309"
                        "paginaFinal" => "318"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vaccination in primary immunodeficiency disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Sobh"
                            1 => "F&#46;A&#46; Bonilla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2016.09.012"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract"
                        "fecha" => "2016"
                        "volumen" => "4"
                        "paginaInicial" => "1066"
                        "paginaFinal" => "1075"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "en representaci&#243;n del Comit&#233; Asesor de Vacunas de la Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a &#40;CAV-AEP&#41;&#46; Calendario de inmunizaciones de la Asociaci&#243;n Espa&#241;ola de Pediatr&#237;a&#58; recomendaciones 2023"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;J&#46; &#193;lvarez Garc&#237;a"
                            1 => "M&#46;J&#46; Cilleruelo Ortega"
                            2 => "J&#46; &#193;lvarez Alde&#225;n"
                            3 => "M&#46; Garc&#233;s-S&#225;nchez"
                            4 => "E&#46; Garrote Llanos"
                            5 => "A&#46; Iofr&#237;o de Arce"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anpede.2022.11.002"
                      "Revista" => array:5 [
                        "tituloSerie" => "An Pediatr &#40;Engl Ed&#41;"
                        "fecha" => "2023"
                        "volumen" => "98"
                        "paginaInicial" => "58&#46;e1"
                        "paginaFinal" => "58&#46;e10"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vaccine use in primary immunodeficiency disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "N&#46; Principi"
                            1 => "S&#46; Esposito"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.vaccine.2014.05.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "Vaccine"
                        "fecha" => "2014"
                        "volumen" => "32"
                        "paginaInicial" => "3725"
                        "paginaFinal" => "3731"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24837766"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immune function in childhood cancer survivors&#58; a Children&#8217;s Oncology Group review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;M&#46;T&#46; Guilcher"
                            1 => "L&#46; Rivard"
                            2 => "J&#46;T&#46; Huang"
                            3 => "N&#46;A&#46;M&#46; Wright"
                            4 => "L&#46; Anderson"
                            5 => "H&#46; Eissa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S2352-4642(20)30312-6"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Child Adolesc Health"
                        "fecha" => "2021"
                        "volumen" => "5"
                        "paginaInicial" => "284"
                        "paginaFinal" => "294"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33600774"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "European Conference on Infections in Leukaemia group&#46; Vaccination of patients with haematological malignancies who did not have transplantations&#58; guidelines from the 2017 European Conference on Infections in Leukaemia &#40;ECIL 7&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Mikulska"
                            1 => "S&#46; Cesaro"
                            2 => "H&#46; de Lavallade"
                            3 => "R&#46; Di Blasi"
                            4 => "S&#46; Einarsdottir"
                            5 => "G&#46; Gallo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1473-3099(18)30601"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Infect Dis"
                        "fecha" => "2019"
                        "volumen" => "19"
                        "paginaInicial" => "e188"
                        "paginaFinal" => "e199"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30744964"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thirteen-valent pneumococcal conjugate vaccine in children with acute lymphoblastic leukemia&#58; protective immunity can be achieved on completion of treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Bate"
                            1 => "R&#46; Borrow"
                            2 => "J&#46; Chisholm"
                            3 => "S&#46;C&#46; Clarke"
                            4 => "E&#46; Dixon"
                            5 => "S&#46;n&#46; Faust"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/cid/ciz965"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2020"
                        "volumen" => "71"
                        "paginaInicial" => "1271"
                        "paginaFinal" => "1280"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31586206"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pneumococcal vaccination during chemotherapy in children treated for acute lymphoblastic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46; Dorval"
                            1 => "S&#46; Gantt"
                            2 => "J&#46;M&#46; Leclerc"
                            3 => "C&#46; Laverdi&#232;re"
                            4 => "P&#46; Ovetchkine"
                            5 => "B&#46; Tapi&#233;ro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/pbc.28944"
                      "Revista" => array:5 [
                        "tituloSerie" => "Pediatr Blood Cancer"
                        "fecha" => "2021"
                        "volumen" => "68"
                        "paginaInicial" => "e28944"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33773013"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Comit&#233; Asesor de Vacunas &#40;CAV-AEP&#41;&#46; Calendarios acelerados&#46; Inmunizaci&#243;n de rescate en ni&#241;os y adolescentes con vacunaci&#243;n inadecuada&#46; Manual de inmunizaciones en l&#237;nea de la AEP&#46; Madrid&#58; AEP&#59; nov&#47;2022&#46; &#91;Accessed 25 March 2023&#93;&#46; Available from&#58; <a target="_blank" href="https://vacunasaep.org/documentos/manual/cap-11">https&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-11</a>&#46;"
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunization in special clinical circumstances"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "American Academy of Pediatrics"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:6 [
                        "editores" => "D&#46;W&#46;Kimberlin, M&#46;T&#46;Brady, M&#46;A&#46;Jackson, S&#46;S&#46;Long"
                        "titulo" => "Red Book&#58; 2021&#8211;2024&#46; Report of the Committee on Infectious Diseases"
                        "paginaInicial" => "67"
                        "paginaFinal" => "105"
                        "edicion" => "32st ed"
                        "serieFecha" => "2021"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Comit&#233; Asesor de Vacunas &#40;CAV-AEP&#41;&#46; Vacunaci&#243;n en ni&#241;os con enfermedades cr&#243;nicas&#46; Manual de inmunizaciones en l&#237;nea de la AEP&#46; Madrid&#58; AEP&#59; nov&#47;2022&#46; &#91;Accessed 15 September 2023&#93;&#46; Available from&#58; <a target="_blank" href="http://vacunasaep.org/documentos/manual/cap-17">http&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-17</a>&#46;"
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EULAR&#47;PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases&#58; update 2021"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;H&#46;A&#46; Jansen"
                            1 => "C&#46; Rondaan"
                            2 => "G&#46;E&#46; Legger"
                            3 => "K&#46; Minden"
                            4 => "Y&#46; Uziel"
                            5 => "N&#46; Toplak"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2022-222574"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2023"
                        "volumen" => "82"
                        "paginaInicial" => "35"
                        "paginaFinal" => "47"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35725297"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current evidence on vaccinations in pediatric and adult patients with systemic autoinflammatory diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;G&#46; Massaro"
                            1 => "M&#46; Caldarelli"
                            2 => "L&#46; Franza"
                            3 => "M&#46; Candelli"
                            4 => "A&#46; Gasbarrini"
                            5 => "G&#46; Gambassi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/vaccines11010151"
                      "Revista" => array:5 [
                        "tituloSerie" => "Vaccines &#40;Basel&#41;"
                        "fecha" => "2023"
                        "volumen" => "11"
                        "paginaInicial" => "151"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36679996"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;R&#46; Bass"
                            1 => "E&#46; Chakravarty"
                            2 => "E&#46;A&#46; Akl"
                            3 => "C&#46;O&#46; Bingham"
                            4 => "L&#46; Calabrese"
                            5 => "L&#46;C&#46; Cappelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.42386"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheumatol"
                        "fecha" => "2023"
                        "volumen" => "75"
                        "paginaInicial" => "333"
                        "paginaFinal" => "348"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36597810"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2&#58; the November 2021 update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;B&#46;M&#46; Landew&#233;"
                            1 => "F&#46;P&#46;B&#46; Kroon"
                            2 => "A&#46; Alunno"
                            3 => "A&#46; Najm"
                            4 => "J&#46;W&#46; Bijlsma"
                            5 => "G&#46;R&#46; Burmester"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2021-222006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2022"
                        "volumen" => "81"
                        "paginaInicial" => "1628"
                        "paginaFinal" => "1639"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35197264"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vaccination in patients with chronic kidney disease&#8212;review of current recommendations and recent advances"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "B&#46;M&#46; Ma"
                            1 => "D&#46;Y&#46;H&#46; Yap"
                            2 => "T&#46;P&#46;S&#46; Yip"
                            3 => "I&#46;F&#46;N&#46; Hung"
                            4 => "S&#46;C&#46;W&#46; Tang"
                            5 => "T&#46;M&#46; Chan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/nep.13999"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nephrology &#40;Carlton&#41;"
                        "fecha" => "2021"
                        "volumen" => "26"
                        "paginaInicial" => "5"
                        "paginaFinal" => "11"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34889005"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Comit&#233; Asesor de Vacunas &#40;CAV-AEP&#41;&#46; Vacunaci&#243;n del ni&#241;o viajero&#46; Manual de inmunizaciones en l&#237;nea de la AEP&#46; Madrid&#58; AEP&#59; nov&#47;2022&#46; &#91;Accessed 15 September 2023&#93;&#46; Available from&#58; <a target="_blank" href="https://vacunasaep.org/documentos/manual/cap-13">https&#58;&#47;&#47;vacunasaep&#46;org&#47;documentos&#47;manual&#47;cap-13</a>&#46;"
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vacunaci&#243;n en viajeros internacionales"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;P&#46; Arrazola"
                            1 => "A&#46; Serrano"
                            2 => "R&#46; L&#243;pez-V&#233;lez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eimc.2016.01.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Enferm Infecc Microbiol Clin"
                        "fecha" => "2016"
                        "volumen" => "34"
                        "paginaInicial" => "315"
                        "paginaFinal" => "323"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26920587"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Australian Immunisation Handbook&#46; Vaccination for international travellers&#46;"
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "CDC&#46; Yellow book 2024&#46; Chapter 2&#46; The Pre-Travel Consultation&#46;"
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "CDC&#46; Yellow book 2024&#46; Chapter 7&#46; Traveling Safely with Infants &#38; Children&#46;"
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ministerio de Sanidad&#46; Cap&#237;tulo 6&#46; Vacunas y enfermedades prevenibles mediante vacunaci&#243;n&#46; Actualizaci&#243;n 2017&#46; &#91;Accessed 15 September 2023&#93;&#46; from&#58; <a target="_blank" href="https://www.sanidad.gob.es/areas/sanidadExterior/laSaludTambienViaja/consejosSanitarios/libroOMS.htm">https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;areas&#47;sanidadExterior&#47;laSaludTambienViaja&#47;consejosSanitarios&#47;libroOMS&#46;htm</a>&#46;"
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "WHO&#46; All updates for travellers&#46;"
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "WHO&#46; International travel and health&#44; 2017&#46; Vaccine-preventable diseases and vaccines Update 2019&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/23412879/0000009900000006/v1_202312211250/S2341287923002788/v1_202312211250/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "33443"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Spanish Association of Paediatrics"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009900000006/v1_202312211250/S2341287923002788/v1_202312211250/en/main.pdf?idApp=UINPBA00005H&text.app=https://www.analesdepediatria.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287923002788?idApp=UINPBA00005H"
]
Share